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Nucleic acids, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are 
polymers of nucleotides. They store, transmit, and translate genetic information in 
living organisms. They are not linear molecules but fold into complex, 
sequence-dependent, three-dimensional shapes. These sequence-dependent shapes 
provide the molecules a capability to bind target molecules and make them like 
antibodies. 
The oligonucleotides which have the ability to recognize and bind ligand 
molecules with a high affinity and specificity are termed 'Aptamer'. They can be 
RNA, single or double-stranded DNA. By SELEX (Systematic Evolution of Ligands 
by EX-potential enrichment), a process similar to the clonal selection and clonal 
expansion in our immune system, aptamers can be selected from a randomized 
oligonucleotide library containing about individual sequences and a large 
amount of variants can be obtained with subsequent rounds of amplification. 
Up to now, aptamers have been designed and found to bind a number of targets 
such as dyes, drugs, nucleotides, proteins, intact cells etc.. With their high specificity 
and affinity, aptamers against disease-associated proteins can be used as therapeutic 
‘ and diagnostic agents. 
In my project, polyclonal and monoclonal aptamers in terms of nucleic acid 
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sequence were selected by using SELEX and their binding specificity was examined 
by Western blotting. The target molecule in our project was cytochrome c which is 
an important protein in apoptosis. Cytochrome c is a small, soluble protein with size 
of 15 kDa. It locates within the intermembrane space of the mitochondria. Upon 
apoptosis, cytochrome c is released from the intermembrane space of mitochondria 
to the cytosol and then activates the downstream caspase cascade to execute 
apoptosis. 
In my study, 9 monoclonal aptamers were selected from a pool of 
oligonucleotides with 40-random-nucleotides sequence between the flanked 3' and 5' 
ends. These selected aptamers was found to bind to cytochrome c with non-specific 
bindings to other cellular proteins in the Western blot analysis. To eliminate the 
non-specific bindings, methods such as counter selection, primer testing and 
different blocking agents were tried. Eventually, one of the monoclonal aptamers 
cy-3 was tested for the semi-quantification of the release of cytochrome c from 
mitochondria in L929 cells after treatment with TNF-a. Results were compared with 
the conventional Western blot analysis by anti-cytochrome c antibody. Our results 
indicate that cy-3 could differentiate the intact cytochrome c and the one released 
from the mitochondria of apoptotic cells. These findings can help us to delineate the 
. mechanism of cytochrome c release during apoptosis. 
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Ch. 1 Introduction 
1.1 Introduction 
The nucleic acids, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), 
are molecular substance to store genetic information. Genetic information flows 
from DNA to RNA by transcription and then to functional protein by translation. 
They had long been thought as solely an inert database for the genetic information 
with limited biological functions since they apparently lack of tertiary structural 
diversity. 
1.1.1. Therapeutic uses of nucleic acids 
Now, nucleic acids are being considered as therapeutic agents, either to interfere 
with the function of specific genes or to bind to specific proteins. Interference can 
occur either at mRNA level using antisense oligonucleotides (Hayward et al., 2003) 
or RNA interference (RNAi) (Grzmil et al, 2003); or at protein level by aptamers 
(Chen et al.’ 2003). 
1.1.1.1. Antisense Oligonucleotides 
After transcription, messenger RNA (mRNA) produced as a single-stranded 
molecule and its sequence of nucleotides is called ‘sense，because it generates a gene 
product (protein). Normally, its nucleotides are ‘read，by transfer RNA (tRNA) with 
anticodons as the ribosome walks along the mRNA during translation. However, 
‘ RNA can form duplexes just as DNA does in the presence of a second stranded RNA 
> 
whose sequence is complementary to the first strand. The second strand is called the 
antisense strand because its sequence of nucleotides is complementary to the original 
'sense' one. When mRNA forms a duplex with a complementary antisense RNA 
sequence, translation is blocked. This occurs because the ribosome cannot read the 
2 
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nucleotides in the mRNA. Alternatively, RNA in duplex form is rapidly degraded by 
ribonucleases in the cell. 
With recombinant DNA technology, synthetic genes (DNA) encoding antisense 
RNA molecules can be introduced into organisms. For example, an artificial gene 
can be constructed to be carried in the genome (DNA) and is transcribed into an 
antisense RNA which is complementary to the mRNA of target. Antisense RNA can 
be used as a tool for therapy. And now, antisense RNA that is complementary to the 
proto-oncogene BCL-2 is being examined as a possible therapy for certain B-cell 
lymphomas and leukemias (Capaccioli et aL, 1996). 
There is another similar strategy of interference called antisense 
oligodeoxynucleotides (ODNs). ODNs are synthetic DNA with 15-20 bases in length. 
Their sequence (3' -> 5') is antisense and is complementary to the sequence of a 
sense mRNA. Therefore, they can form duplex with mRNA and also block its 
translation. Antisense ODNs was tested against HIV-1 (Zamecnik et al” 1986; 
Freund et al； 2001), cytomegalovirus (CMV), asthma (Ball et al., 2003) and certain 
cancers (Baron et aL, 2003; Leamon et aL, 2003) etc.. The U. S. FDA has approved 
fomivirsen, an antisense ODN that degrades the mRNA of two essential viral 
proteins for the treatment of CMV infections in the eye (Grillone et al.’ 2001). 
3 
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h坤://perso.club~intemetfr/ajetudes/nano/antisense.htm 
Fig. 1.1. Antisense oligonucleotides 
Antisense oligonucleotides are synthetic RNA or DNA fragments which 
are complementary to mRNAs. After the introduction into cells, they bind 
to their complementary mRNA and, block the corresponding protein 
translation. -
1.1.1.2. RNA Interference 
* 
) 
RNA molecules appeared in the cytoplasm normally are in single-stranded form. 
If a RNA molecule is in the form of duplex, an enzyme (the one in Drosophila has 
been named Dicer) usually cuts this double-stranded RNA (dsRNA) into fragments 
of 21-23 base pairs ( � 2 turns of a double helix) (Zamore et al., 2000). 
4 
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The two strands of each fragment then separate and the antisense strand can 
bind to the complementary sense sequence of a new mRNA molecule. This then 
elicits the cutting of the mRNA and destroys its ability to be translated into protein. 
Because of this activity, the double-stranded RNA fragment has been named "short 
(or small) interfering RNA" (siRNA). 
A DNA vector that can continuously synthesizes a siRNA corresponding to the 
gene that it wants to block has been reported in mammalian cells (Bmmmelkamp et. 
al 2002). 
1 ^ Dicer 
^ ^ ^ I ^ ^ ^ ^ ^ ^ R N A Fig. 1.2 Mechanism ofRNAi 
2 » dsRNAs (typically >200 nucleotides) can 
么 f RISC protein I . j / ‘i_ . 丄 
.1 comp6nents | DC used to suppress the expression of 
target genes in many organisms and cell 
s. RljC types. After introducing into cells, the 
dsRNAs enter the RNA interference 
(RNAi) pathway, a common cellular 
3 • SiRNA unwinding pathway. First, the dsRNAs were cut into 
• 20-25 nucleotides small interfering RNAs 
广s. Artivatftd (siRNAs) by an RNase Ill-like enzyme 
called Dicer (1). Then, the siRNAs form 
^ 乂 endoribonuclease-containing complexes 
4 i Association with hown as RNA-induced silencing 
• target mRNA complexes (RISCs) (2). The siRNA 
-r-iw ^―^ strands are then unwound and became 
J^S^^ 夕 single stranded (3). The antisense siRNA 
strands subsequently guide the RISCs to 
5 • complementary RNA molecules (4)， 
母 where they cut the cognate RNA (5). 
Target mRNA 
^ ^ deavage 
Sense "ftrget mRMA 
^•Xh^ Andsttnse 
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1.1.1.3. Aptamer 
In the early of 1990s, natural occurring RNAs were found to bind small 
molecules. For example, the group I introns can bind guanosine nucleotides with a kd 
of approximately 0.5 mM (Herschlag and Cech, 1990). Also, part of the binding site 
has been found to bind a base triple between a G-C base pair on the RNA. 
Small nucleic acids were then found to fold into complicated 3-dimensional 
shapes which have binding specificities to many small molecules (Ellington et a/•， 
1992; Gold, 1995). 
Oligonucleotides with selective binding capability which is selected by the 
combinatorial chemistry method SELEX (see later) from a pool of random 
nucleotide library is called 'Aptamer' or oligobody. Normally, they have a unique 
sequence that can fold into a specific 3-dimensional structure for ligand binding with 
a high affinity and specificity. The term 'Aptamer' is derived from a Latin word 
"aptus" which means “to fit” (Ellington, et al., 1990). 
\ 
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1.2 Selection of aptamer 
In 1990, RNAs with specific binding properties was firstly isolated from 
libraries of random RNAs by Tuerk and Gold (1990) and by Ellington and Szostak 
(1990). The technique of selection of these RNAs was called in vitro selection or 
SELEX (^stematic Evolution of Ligands by Exponential Enrichment) (Ellington 
and Szostak, 1990). 
1.2.1. SELEX ‘Systematic Evolution of Ligands by Exponential enrichment， 
Using SELEX process, oligonucleotides can be selected efficiently from 
randomized libraries of RNA, DNA, or modified nucleic acids that bind target 
molecules with high affinity and specificity. This process started from a pool of 
oligonucleotides with random sequences in the core with two flanked known 
sequences and involves steps of selection and amplification. 
The randomization of a sequence from 25 up to 100 nucleotides in length has 
been used to produce target-specific aptamers. Because the three-dimensional 
structure of short single-stranded nucleic acids are dictated by their sequences, such 
a library contains a large number of molecular shapes or conformations. For the 
diversity, the target recognition increases with the length of random sequence. By 
composed of the 4 different nucleotides, the diversity of the sequence in the library 
‘ should be 4" (where n is the number of nucleotide in the random sequence). For 
example, a library containing a 40-nucleotide random region is represented by 1.2 x 
1024 individual sequences = 1.2xlO�*). However, in practice, due to the 
chemistry limitation, the complexity of oligonucleotides library is limited to to 
10i5 individual sequences. 
7 
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1.2.1.1. In vitro selection 
In vitro selection is a step to separate the oligonucleotides with high affinity to 
its ligand from the random library. This can be done by using affinity 
chromatography (Deng et aL, 2001), immimo-precipitation by magnetic beads 
(Bruno et al., 2002), electrophoretic mobility shift assay, filter-binding techniques 
(Gal, 1997), or functional activity. For the selection using solid support for 
separation, target molecules are first conjugated on solid support like PVDF 
membrane, agarose beads or magnetic beads (Ishizaki et a!., 1996). 
Selection can be initiated by allowing the oligonucleotide library to react with 
the target molecules under a favorite binding condition (suitable buffer, pH and 
temperature). The aptamers selected under the selection condition must be used in 
such condition afterwards. (Lorsch et al., 1994) 
During the selection, the unbound oligonucleotides are separated from those 
bound to the target molecules by wasting the solid support with binding buffer; by 
filtration with the use of suitable filter or by the different mobility between the 
complexes and the free unit in a separating gel. Subsequently, the bound 
oligonucleotides are then eluted and are eventually purified from the target 
molecules and precipitated by ethanol. 
» 
1.2.1.2. Amplification 
The bound oligonucleotides isolated are then amplified by reverse transcription 
and PGR (for RNA-based libraries) or just asymmetric PGR (for DNA-based 
libraries) (Innis et aL, 1988) with primer pairs which are complementary to the 
8 
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flanked ends of the oligonucleotides pool. Then a pool enriched in sequences that 
bind to the target protein is generated. This library is then transcribed in vitro (for 
RNA-based libraries), or its strands are separated (for DNA libraries) to generate 
molecules for use in the next round of selection. 
Taiget on membrane 
^ m k J 
Pool of oligonucleotides • • 
國：圓 
Fig. 1.3. Aptamer selection scheme showing one round of an in vitro 
selection against a protein taiget dotted on PVDF membrane. 
(1) A libraiy of oligonucleotides first incubates with targets dotted on a 
membrane. (2) After washing, the bound oligonucleotides are eluted from 
the targets. (3) Asymmetiy PGR is performed to amplify the selected 
oligonucleotides. One round of selection is completed. (4) Another round of 
selection then starts with the amplified oligonucleotides. Several rounds of 
selection and amplification are carried out. 
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1.2.1.3. Monoclonal aptamer 
After several rounds of selection and amplification, usually 5-15 rounds, 
SELEX is completed and polyclonal nucleic acids with high affinity and specificity 
are selected against the target. The pool of the nucleic acids isolated can then be 
cloned and monoclonal nucleic acid can be obtained. 
1.2.2. Photo-SELEX 
A special type of aptamer known as photo-aptamer, is developed that bears 
photocross-linking functionality. Photo-aptamer can be generated by incorporating 
the 5 -halo-deoxyuridine such as 5-bromo-2'-deoxyuridine (BrdUrd) or 
5-iodo-2 ‘ -deoxyuridine in place of thymidine in the oligonucleotides library. And the 
photo-cross-linking usually takes place between the C-5 position of the nucleobase 
and an electron-rich amino acid such as Tyr and Trp at close proximity under UV 
illumination (Smith et al.，2003; Golden et al, 2000). 
During selection, the pool of photo-aptamers is first incubated with the target. 
After binding, the solution was irradiated by a short wave (254 or 266 nm) UV light 
or 308nm light for cross-linking. UV light or light at 308 nm elicits photoelectron 
transfer from a nearby electron donor to the bromouracil base via either excitation of 
the BrdUrd, excitation of the electron donor, or excitation of a BrdUrd-electron 
donor charge transfer state and finally, unbreakable cross-linking forms. Amino acids 
> 
residues that can serve as electron donors in BrdUrd photocross-linking include Tyr, 
Trp, His, Phe, Cys, Cys-Cys, and Met. Among these residues, Tyr and Trp are 
excited at 308 nm. 
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Photocross-linking can enhance the specificity of the aptamer-protein 
interaction. Although a protein may bind an aptamer nonspecifically, the probability 
that an appropriate amino acid would be positioned to cross-link with a BrdUrd 
residue would be low. 
穩 f --
V / 
Modified frtMn http://www<sonialogic.coin/sciaicc/photoseiexJitinl 
Fig. 1.4. Photo-SELEX scheme 
(1) The oligonucleotides first incubate and bind to the target. (2) After 
washing, laser pulse or UV light is applied. Photo-cross linkages only form 
between those oligonucleotides bind to their targets in the right position. (3) 
At high temperature, proteins and aptamers become denatured and those 
without cross linkage were washed away. (4) The oligonucleotides isolated 
are then released by protease which digests the target molecules. 
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1.3 Examples of target molecules of aptamers 
Up to now, aptamers have been developed for a wide variety of targets with 
dissociate constant typically range from nanomolar to picomolar or even sub 
picromolar affinity (Burgstaller et al., 2002; Pavski et al., 2003; Uphoffe/ al., 1996). 
These target molecules include proteins, peptides, dyes, amino acids, 
nucleotides, and drugs (Deng et al.’ 2001), metal ions (Hofmann et al., 1997)， 
organic dyes (Ellington et al., 1992), drugs (Mannironi et al., 1997), amino acids 
(Geiger et al., 1996), co-factors (Wilson et al.，1998), aminoglycosides (Wang et al., 
1996), antibiotics (Wallace et al., 1998)，nucleotide base analogs (Kiga et al” 1998), 
nucleotides (Haller et al., 1997) and peptides (Williams et al., 1997). There are a 
growing number of protein targets to which selected aptamers bind. These include 
enzymes (Bridonneau et al., 1998)，growth factors (Pegratis et al., 1997)，antibodies 
(Wiegand et a!” 1996), gene regulatory factors (Lochrie et al” 1997), cell adhesion 
molecules (Kraus et al., 1998), and lectins (Bridonneau et al” 1999). Some of the 
examples are summarized in Table 1.1. 
t 
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Table 1.1 Examples of aptamers selected 
Type Example Reference 
Non-structural protein 3 protease 
p Nishikawa et al, 2003 
Enzyme of hepatitis C vims 
ERK2 Bianchini etal., 2001 
Basic fibroblast growth Factor 
^ , ^ , … … Golden etaL, 2000 
Growth factor (bFGF) 
Keratinocyte growth factor (KGF) Pagratis et al., 1997 
n Coagulation factor IXa Rusconi et al., 2002 
Peptide  
Nucleocapsid protein of HIV-1 Kim et al, 2002 
Antibodies Myasthenic Autoantibodies Hwang et al, 2002 
A . . Tetracycline Berens et al., 2001 
Antibiotic  
Streptomycin Wallace etaL, 1998 
Dyes Sulforhodamine B Wilson etaL, 1998 
Cibacron Blue 3GA，Reactive Red ” 
… Elington et al, 1990 
120, Reactive Green 19 etc. 
, . . � Arginine Nolte etaL, 1996 
Ammo acids  
Isoleucine Majerfeld etaL, 1998 
Nucleotides AMP “ Burke et al.’ 1997 
* -
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1.4 Applications of aptamer 
Until now, many aptamers were selected against different targets including 
disease-related proteins and analytical targets. Many different applications were also 
developed. These applications of aptamers include rapid target validation (Rhodes et 
a/., 2000), pathway dissection (Seiwert et al, 2000), the discovery of diagnostic 
reagents (Hicke et al” 2000; Brody et al., 1999) and novel therapeutics (Floege et aL, 
1999). 
1.4.1. Detection of aptamer 
There are three methods commonly used for the detection of aptamers, They are 
radiolabeling，biotin - streptavidin system and fluorescent labeling. 
For radiolabeling, radiolabeled ATP is used and incorporated into aptamer 
during amplification by PGR. With radioactive aptamers, the amount of bound 
aptamers with the target obtained by filtration can be easily estimated by scintillation 
counting. Alternatively, the presence of aptamer after probing protein on membranes 
or mobility shift in gel can be easily detected by exposing the complex to x-ray 
films. 
For the biotin - streptavidin detection system (Gretch et al” 1987)，aptamers are 
first amplified by PGR with the use of biotinylated 5' forward primer. After several 
rounds of amplification, the PGR products are all biotinylated. After the binding of 
aptamer to the protein, the biotinylated aptamer can be detected by streptavidin. The 
streptavidin usually conjugates with an enzyme such as horseradish peroxidase or 
alkaline phosphatase. In the presence of suitable substrate, chemiluminescence signal 
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or colour change can be measured by X-ray films or colorimetric reader. 
The use of fluorescent labeling is similar to that of biotin. In the PGR, FITC 
conjugated 5，forward primers are used. The FITC conjugated PGR products can be 
used for target labeling. Signals on the aptamers can then be detected directly by 
x-ray films or fluorometric reader. However, photo-bleaching may occur during the 
processing of the fluoro-aptamer. 
1.4.2. Examples of diagnostic use 
With their easy labeling and their high specificity and high affinity, DNA 
aptamers been exploited in diagnostic applications with biosensor (Potyrailo et al., 
1998) and flow cytometer (Davis et al., 1996). 
1.4.2.1. Aptamer against theophylline with high specificity 
One of the important features of antibody or aptamer is the binding specificity 
to target molecules or antigens. Theoretically, the diversity of antigen-binding sites 
of aptamers is equivalent to, if not greater than that of antibody. Below are some of 
the examples showing aptamer specificity. 
Theophylline is a natural occurring alkaloid that is used widely as 
.bronchidi lator in the treatment of asthma, bronchitis, and emphysema. However, its 
t 
therapeutic index is narrow and the serum level should be monitored careftilly to 
avoid toxicity (Hendeles et al.，1983). In serum, the presence of theobromine (3， 
7-dimethylxanthine), which is chemically similar to theophylline may affect the 
result of monitoring theophylline serum level, like caffeine. Diagnostic methods 
15 
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must be developed to discriminate efficiently among these compounds. 
Species of RNA that bind with high affinity and specificity to theophylline were 
identified by SELEX from a pool of 10)4 oligonucleotide library with 40 random 
nucleotides (Jenison et al, 1994). One of the RNA aptamers selected bound to 
theophylline with a dissociation constant Kd of 0.1 ^M. When compared the binding 
of this RNA aptamer to caffeine which differs from theophylline only by a methyl 
group at nitrogen atom N-7, the binding affinity with theophylline is 10,000-fold 
greater than that of caffeine suggesting that the binding specificity of aptamer is very 
high. 
The discrimination of the aptamers between theophylline and caffeine can be 
achieved by "counter-SELEX". In the selection of aptamer against theophylline, 
counter selection was done after the fifth round of selection by eluting those bound 
aptamers by caffeine before using theophylline. The aptamers eluted by caffeine 
were then discarded and those eluted by theophylline were collected. The aptamers 
so selected can discriminate theophylline from caffeine. 
1.4.2.2. Aptamer chip 
Recently, aptamers for different targets are synthesized and dotted on a 
micro-chip or an array. By using arrays, it ultimately allows the simultaneous 
measurement of the concentrations of hundreds or thousands of targets in a broad 
range of sample types. And thus they can be used for diagnosis of disease. Now, 
there are three different types of array, DNA array, protein array and aptamer array. 
16 
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For the DNA array, genes are dotted on the specific site of a chip. After 
exposure to an mRNA sample, the complementary strands are hybridized with DNA. 
With appropriate signal generation system, signals such as fluorescence can be 
generated from the chip and the change of mRNA expression level can be 
determined. 
For protein and aptamer array, antibodies or aptamers for specific targets are 
dotted on the chip. After exposure to the samples such as cell lysate, blood or urine, 
the specific targets are bound on the chip. For protein chip, the detection of the 
specific target should be done by the aid of secondary antibody conjugated with 
enzyme or fluorescent indicator. While for the aptamer chip, since the aptamer are 
not protein in natufe, the presence of the protein bound on the chip can easily be 
detected by common protein stains. With a database generated from the pattern of 
normal and disease samples, the disease state of a patient can be easily analysized by 
comparing the patients' pattern with the database (Kodadek, 2002; Petach et al, 
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Diagnosis with 兮 �^ ^ ^ H 
Aptamer Array . 
’ , ^ ^ ^ ^ ^ ^ • A p t a m e r Chip 
Protein H H H ^ H i p ^ H 
Scanning Z ( 2 j 
H H m ^ ^ l H to remove I S ^ ^ ^ s M t K m 
國 
E x p o s ^ to laser t o Exposed to a 
Cross-link proteins with ap t amers bloodfurine sample 
Fig. 1.5. Diagnostic use of aptamer - Aptamer array 
For the diagnosis with aptamer array, aptamers are first dotted on a chip 
(1). Then the chip is exposed to a clinical sample such as urine or blood 
(2). After binding, the unbound proteins are washed away (3) and cross 
linking can be obtained by laser or UV exposure (4). The proteins on 
aptamers can then be stained (5). By this method, concentration of ten of 
thousands proteins can be measured simultaneously. 
1.43. Examples of therapeutic use 
I 
1.4.3.1. Vascular endothelial growth factor (VEGF) 
Aptamer can be used as a therapeutic agent. One of the advantages of using 
aptamers is their non-immunogenic feature due to their small size and similarity to 
endogenous molecules. 
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Aptamers against vascular endothelial growth factor (VEGF) is a good example. 
VEGF is an angiogenic promoter present in a wide variety of human tumors and is a 
well characterized specific endothelial mitogen and permeability factor (Leung et al.’ 
1989). Its level was found to be upregulated in the majority of human tumors. Also, 
it has been established recently that VEGF is a survival factor for endothelium in 
new blood vessels (Gerber et al., 1998). It was found that a deletion of 1 allele in the 
VEGF gene with result in abnormal development that leads to embryonic lethality. 
Thus, VEGF is a potential target for novel anti-tumor therapies. 
Anti-VEGF antibody was reported to suppress the growth of tumors effectively 
(Rowe et al., 2000, Borgstrom et al., 1998). However, this antibody recognizes all 4 
isoforms of VEGF which are expressed by alternative splicing: VEGF 121, 165, 189 
and 206 (Backer et al., 2001). One of these, VEGF 165, appears to be expressed 
predominately in adult human tumors but its role in pediatric cancers has not been 
established. If other isoforms support the physiologic angiogenesis associated with 
tumour growth, narrowing the target to'a tumor-associated isoform might provide 
benefits in pediatric patients. 
Recently, an isoform-specific anti-VEGF 165 aptamer with high affinity and 
nuclease resistant property (fluoropyrimidine modified RNA-based aptamer) was 
, characterized (Ruckman et aL, 1998). This specific aptamer is known as NX1838 
and was found to suppress the primary tumor growth and metastasis of Wilms tumor 
through the inhibition of vascular cell proliferation and vascular permeability (Huang 
et aL, 2001，Ruckman et al.’ 1998，Ostendorfer al., 1999). 
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1.4.3.2. Aptamer as a reversible antagonists of coagulation factor IXa is another 
example to show the potential use of aptamers as therapeutic agents 
The blockage of blood vessels by abnormal blood clots is one of the biggest 
causes of serious illness and premature death in Western societies. Normally, the 
patient is treated with heparin which is an effective anti-coagulant. However, heparin 
may induce an autoimmune disease called thrombocytopenia that resulted in a 
reduction in platelet count and prolonged subcutaneous bleeding. Also, heparin does 
not have rapidly acting antidote. It is therefore very dangerous as significant 
bleeding due to imbalance of coagulation and anti-coagulation may lead to an 
increase in morbidity and mortality of patient. 
Aptamer specific for coagulation factor IXa which is the key factor of both the 
intrinsic and extrinsic pathway of the coagulation was developed (Rusconi et al.’ 
2002). The aptamer was selected from a combinatorial library of 
oligonucleotides with 40 random nucleotides sequence. After eight rounds of 
selection, aptamer that is 5,000 times more specific for Factor IXa than that for the 
structurally related factors such as Factor Vila, Xa, XIa was selected. After the 
aptamer binds to the coagulant factor IXa, it blocks the activation of Factor IXa by 
Factor Vila or prevents the activation of Factor X by Factor IXa together with Factor 
Villa. 
The antidote which can reverse the anti-coagulant effect of the selected aptamer 
is also characterized. For an antidote to neutralize the effects of aptamers, it is only a 
sequence that is complementary to the critical and functional base pair of the aptamer. 
After the antidote binds with the aptamer, it blocks the binding site of the aptamer to 
Factor IXa, thus eliminating the anti-coagulant effect. 
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1.4.4. Problem faced by aptamer 
1.4.4.1. Stability 
For the use of aptamers with biological samples, nuclease attack is one of the 
major problems. Unmodified oligonucleotides, especially RNA, are degraded easily 
by nuclease which is commonly present in biological fluids. The in vitro half-life of 
a typical RNA oligonucleotide in plasma is a few seconds. This limits RNA aptamer 
to be used as measure analytes or therapeutics agents in biological fluids that contain 
nucleases. 
However, this can be overcome by chemical modification of oligonucleotides. 
Since ribonucleases utilize the 2'-0H group for the cleavage of the adjacent 
phosphodiester bond and the nucleases that are most abundant in biological fluids 
appear to be pyrmidine-specific endonucleases, substitution of the 2'-position of 
pyrimidine nucleotides with 2'-amino (2'-NH2) (Rusconi et al., 2000), 2，-fluoro 
(2’-F), or a variety of 2'-0-alkyl moieties makes the oligonucleotides resistant to 
ribonucleases with an in vitro half-life in'the 5-15 hour range (Jayasena et al., 1999). 
Synthetic phosphodiester-modified oligonucleotides such as phosphorothioate 
oligonucleotide (S-ODN) and phosphorodithioate oligonucleotide (S2-ODN) analog 
can also increase nuclease resistance and can bind to proteins with enhanced affinity. 
, Unfortunately, ODNs possessing high fractions of phosphorothioate or 
I 
phosphorodithioate linkages appear to lose some of their specificity and are ‘sticker, 
toward proteins (Yang et al, 2002). Thus, the ratio of modification must be adjusted. 
ODN modification makes aptamer suitable for both diagnostic and therapeutic 
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applications. When comparing unmodified RNA with unmodified DNA, unmodified 
DNA sequences are generally more nuclease resistant and the in vitro half-life of a 
typical DNA oligonucleotide in plasma is about 30 to 60 minutes. Therefore, it is 
reasonable to assume that DNA aptamers without ftuther modifications can be used 
in diagnostic assays in which aptamers may come into contact with biological fluids 
for a brief period of time. If necessary, additional protection from exonucleases can 
be provided through terminal capping with small molecules such as an amino linker, 
a phosphate group, or an inverted thymidine residue. For most diagnostic formats, 
terminal modification of aptamers is a common practice and provides a route to 
conjugate aptamers either to reporter molecules or to solid supports. 
Apart from modification, another possible way to protect RNA from nuclease 
degradation is by mirror image. This method is indirect and consists of two steps: in 
the first step, an aptamer is selected to bind the enantiomer of the target, then in a 
second step, the enantiomer of the aptamer is synthesized (from L-phosphoramidites) 
as a nuclease-insensitive ligand of the natural target. This mirror-image approach has 
been applied to L-arginine, D-adenosine, and the peptide hormone vasopressin 
(Famulok etai, 2000). 
1.4.4.2. Clearance from blood 
Apart from stability, clearance from blood is another problem for the 
» 
therapeutic use of aptamer. Due to the small size of an aptamer (an aptamer with 40 
nucleotides in length is nearly 13200 Da in molecular weight), they are cleared from 
animals via the kidneys in minutes. Therefore, for a stable aptamer, the in vivo 
plasma half-life is governed by the rate of clearance from the animal. 
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The clearance rate of an aptamer can be altered by increasing its effective 
molecular size rationally, such as by the site-specific addition of various molecular 
weight polyethylene glycol (PEG) moieties or other hydrophobic groups, or by 
attachment of the aptamer to the surface of a liposome. After the modification, a 
given aptamer can be formulated to have a longer half-life. 
t 
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1.5 Comparison between aptamer and antibody 
1.5.1. General comparison between aptamer and antibody 
1.5.1.1. Diversity 
Between aptamer and antibody, the most obvious difference is that aptamer is 
nucleic acid in nature while antibody is protein. This makes aptamer become more 
stable in extreme condition when compare with antibody. Also, direct protein 
staining can be applied in the diagnostic use of aptamer since it is not protein in 
nature. However, antibody can only be recognized by secondary antibody which 
conjugated with an enzyme and finally produces colour product or 
chemiluminescence. Moreover, the production of aptamers can be controlled more 
easily since they are selected in vitro while antibody is usually produced in vivo. 
Antibody is composed of 2 heavy and 2 light chains. And their diversities 
depend on the combination of the gene segments of V, D, J and N region. Light 
chains consist of V and J gene segments at the variable region while heavy chains 
consist of V, D and J gene segments. By rearranging different segments of V, D, J 
and N regions in the pool of stem cells, a large diversity of light chains and heavy 
chains is resulted. With different combinations of light chain and heavy chain, 
diversity of about 1.4 X different antibodies is resulted (Fig. 1.6). 
Aptamer is a single chain consists of a random region in two flanked ends. The 
diversity depends on the different arrangements of the four nucleotides in the random 
region. For a pool of oligonucleotides with 40 random nucleotides sequences, its 
sequence diversity is -1.2 X However, the diversity of the random 
sequences is limited to the DNA synthesis chemistry that is about 
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Recombinat ion o T V - J - D gene segment of heavy chain 
^ l i i i i i n M K a i K f l m K 
L V„1 L S o L V ^ J1 J2 Js J4 J s Ch 
Rearrament of DNA 
Cell DNA { m n i i m B ？ ^ r 
L � 1 L S o J2 JS J4 J s C|a 
Transcription 
T r a n s c r i p t L v ^ J2 Js J4 J s c ^ 
mRNA u W ^ m ^ M 
L V„2 J2 Ch 
Heavy Chain | i  
http://ntri.tamuk.edu/immimology/abproductioii2.htiiil 
Antibodies (BCRs) Gene Segments Combinations 
V 32 
J 5 
N regions 100 1.6 x 10* L chains 
V„ 50 
Dh 29 ' 
JH 6 
N regions 100 8.7 x 10® H chains 
Any H chain with any kappa L chain 1.4 x 10^ ® 
Fig. 1.6. The production of a heavy chain of IgG by rearrangement of V， 
D, J and N segments and the table below shows the diversity of 
antibody. 
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1.5.2. Specificity 
From the pervious study, aptamers were shown to have high specificity. For the 
aptamer against VEGF therapeutic use, it can recognize the VEGF isoform 165 
among 4 subtypes which are slightly different while antibody cannot differentiate the 
four isoforms. 
1.5.3. Disadvantages of antibody 
Antibodies are usually raised in vivo and their performances are dependent on 
the responsiveness of hosts. Poorly immunogenic and toxic molecules are difficult or 
impossible to raise antibody. Also, the use of antibodies is restricted by the in vivo 
parameters that antibodies are not compatible to extreme conditions other than 
physiological environment. Even the same type of antibody, different batches of 
antibody varies and immunoassays are required to be optimized with each new batch 
of reagents. 
Production of monoclonal antibodies can be done in vitro with in vitro 
immunization. However, monoclonal antibody production is laborious and expensive. 
After screening a large number of colonies, target clone has to be expanded in vivo 
or in vitro for antibody production. From time to time, frozen stocks of 
antibody-producing cells must be stored at multiple sites in case of accidental losses 
or the death of cells lines. Still, hybridomas and animals must be kept alive during 
) 
the production process. 
Also, antibodies are large in size and complexity. This makes them difficult to 
be modified with enzymes or labeling agents. Sometimes, modification may reduce 
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the affinity of antibody. Also, antibodies tend to be denatured, they lose their 
structure when they are heated or exposed to extreme pH (Drolet et al., 1996). 
1.5.4. Advantages of aptamer 
On the contrary, aptamers are selected in vitro, the processes do not involve 
animals, cells, or even in vivo condition. As a result, variation between individual 
animals or cells can be eliminated. Also, their productions are by chemical synthesis 
with extreme accuracy and reproducibility. Therefore, the product performance is 
expected to have no or little batch-to-batch variation. By in vitro selection, aptamers 
for molecules that are toxic or that do not elicit good immune responses can also be 
generated. By using in vitro selection, the properties of aptamers can be changed on 
demand according to the uses of aptamers. For example, aptamers can be selected to 
bind to a target in a nonphysiological buffer and at nonphysiological temperature. 
After selection, once the sequences of aptamer have been identified, they can be 
synthesized in large quantities and are'reproducible in any laboratory with stable 
performance. Furthermore, the price for aptamer production is relatively low. 
Aptamers are usually 15 times smaller than that of a typical IgG antibody and 
they can be easily modified. For example, reporter molecules such as biotin and 
fluorescein can be conjugated to aptamers at precise locations. Different functional 
) 
groups that allow subsequent modification of aptamers with other molecules can also 
be conjugated during the chemical synthesis of aptamers. Although modification of 
aptamer may also reduce the affinity, this can be overcome by ‘Post-SELEX，. That 
means the high affinity aptamer with suitable modification can be selected again 
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with a modified polynucleotide library while the modification can be designed 
according to the final use of the aptamer. 
Moreover, aptamers can undergo reversible denaturation that they can be 
renatured after exposure to denaturing conditions such as heat, salt concentration, pH 
of the medium, and chelating agents. Also, they are stable to long-term storage and 
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1.6 Project objectives 
In this project, cytochrome c is the target of the aptamer selection. 
Cytochrome c is a small, soluble protein of 15 kDa in size and is localized in 
the mitochondrial intermembrane space and is loosely attached to the surface of the 
inner membrane. On cytoplasmic ribosomes, apocytochrome c is synthesized and 
then translocated into the mitochondria. There is a covalent attachment of the 
apocytochrome c and the heme group that is synthesized in mitochondria and this 
creates functional cytochrome c (Vander Heiden and Thompson, 1999). Cytochrome 
c is a requisite component of the mitochondrial respiratory chain and participates in 
the electron transfer between complex III and complex IV of the respiratory chain in 
mitochondria for the production of ATP. 
On the other hand, cytochrome c is released from the intermembrane space of 
mitochondria into the cytosol due to the opening of the mitochondrial permeability 
transition pores in response to a variety of apoptotic stimuli (Mignotte and Vayssiere, 
1998; Single et al” 1998; Skulachev, 1998). Cytosolic cytochrome c is an essential 
component of the vertebrate apoptosome which is composed of cytochrome c, 
Apaf-1, and procaspase-9 (Apaf-3). Interaction of these proteins leads to the 
activation of caspase-9, which in turn activates other caspases (such as caspase-3) 
ultimately resulting in cell death (Green and Reed, 1998). Therefore, the release of 
‘ cytochrome c is one of the hallmarks of apoptosis. 
For the time being, release of cytochrome c from apoptotic cells is detected by 
Western blot analysis with antibody. In this project, aptamers against cytochrome c 
were selected from a pool of oligonucleotides as a substitute of anti-cytochrome c 
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antibody. Also, we tried to streamline the process for selecting useful aptamer. 
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A list of the common name，chemical name and formula of chemicals used in this 
project. 
Common name, Chemical name and formula Formula Source 
Weight 
2-mercaptoethanol 化,~ Sigma Chemical Co.， 
(C2H6OS) St. Louis, MO, USA 
Acetate  
Acetic acid � ^ BDH Chemicals Ltd., 
(CH3COOH) Poole, England 
Acrylamide/bis-acrylamide . Sigma Chemical Co., 
(30% solution, mix ratio 37.5:1) St. Louis, MO, USA 
- Sigma Chemical Co.,  
Agarose ‘ st. Louis, MO, USA 
Albumin, Bovine rhemical Co 
(BSA, initial fractionation by cold alcohol / ^t Louis MO USA�  
precipitation, Fraction V 96-99% albumin) ‘ ， , 
A . ,4. . "^ ；；^ BIO.RAD  
Ammonium persulfate 228.2 Laboratories 
Aiiti;(^ytochro=ca，body ； Pharmingen  
Clone no. 7H8.2C12 ^ 
Streptavidin antibody-HRP conjugated antibody / Pharmingen 
(mouse horseradish peroxidase conjugated)  
Anti-mouse-HRP conjugated antibody 丨 BIO-RAD 
(mouse horseradish peroxidase conjugated) Laboratories 
Aprotinin . Sigma Chemical Co., 
( 3 - 7 TIU (trypsin inhibitor unit)) St. Louis，MO, USA 
BCA I Sigma Chemical Co., 
- (Bicinchoninic acid solution) St. Louis, MO, USA 
Bromophenol blue 洲 q Sigma Chemical Co.,  
(Ci9H9Br405SNa) St. Louis, MO, USA 
‘ ^ ^ n L n ^ T " 119.38 Merck, Germany 
� (CHCI3) I 
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Commassie brilliant blue R-250 oor n (卞ite? S^tes 
Tj XT c XT \ 826.0 Biochemical),  
(C45H44_2Na) Cleveland, OH, USA 
Cytochrome c, Horse 12,384 ^ i f Z ^ ^ u S ^ ^ A 
Sangon Biologic 
Deoxynucleotide set , 了 Engineering 
(dNTP) (dATP, dTTP, dGTP, dCTP) S ^ c T c o 
Ltd., .Shanghai, China 
/ ^ i ^ J o ^ n 1,228 Merck, Germany  (C56H92U29)  
DNA marker GibcoBRL, L i f e ^ 
(25 base pair) Technologies Inc. 
ECL reagents ^ Amersham Pharmacia 
(Enhanced chemiluminescence reagents) Biotech  
Ethanol BDH Chemicals Ltd., 
(EtOH) (C2H5OH) Poole, England 
Ethanolamine  
Ethidium bromide … Molecular Probes, 
(EtBr) Eugene, Oregon, USA 
Ethylenediaminetetraacetic acid ？q? 9 Sigma Chemical Co., 
(EDTA) (C10H16N2O8) St. Louis，MO, USA 
i j x T i S二“ .. A -J _ Amersham Pharmacia N,N,N',N'-tetraacetic Acid 380 , 
(EGTA) (C14H24N2O10)  
Fetal Bovine Serum , GibcoBRL, Life 
(FBS) Technologies Inc. 
„ /lAAnnn Amersham Pharmacia Ficoll 400,000 D. ‘ 1 : ‘ Biotech  
Formamide . . Sigma Chemical Co., 
(CH3NO) St. Louis，MO, USA 
eine USB (United States 
/TT >jrH r n m 75.07 Biochemical),  
(H2NCH2CO2H) Cleveland, OH, USA 
(N-[2-hydroxyethl]piperazine-N'-[2-ethanesulfonic 238.8 g f ^ ^ i l ^ e ^ ^ a l u i ^  
acid]) . ouis， ， 
Hydrochloric acid ^^ BDH Chemicals Ltd., 
(HCl) Poole, England 
Isoamyl alcohol «« Riedel-de Haen, AQ 
(3-methyl butanol-(l)) (C5H12O) ^ ^ Germany 
Isopropanol � , BDH Chemicals Ltd.,  
((CH3)2CH0H) 而 Poole, England 
Isopropyl-b-D_t=ga!actopyraiioside 282.4 ^ ^ ^ c h ^ c l T '  
( 叫 Cleveland, OH，USA 
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Leupeptin Sigma Chemical Co., 
(C20H38N6O4) St. Louis, MO, USA 
Lysine 1 幻 ^ Sigma Chemical Co., 
((L-2,6-Diaminohexanoic acid) monohydrochloric) . St. Louis，MO, USA 
Low range marker for Western blot / BIO-RAD  
Laboratories 
Magnesium chloride ^^ ^ ^ Sigma Chemical Co., 
(MgCb) St. Louis, MO, USA 
Magnesium sulfate-7-hydrate • 似 BDH Chemicals Ltd., 
(MgS04-7H20) 應 补 Poole, England 
Methanol ” ^ BDH Chemicals Ltd., 
(CH3OH) 仏 P o o l e , England 
Molecular sieve , . . 
(Potassium, Sodium alumino-silicate) (nominal pore / ^^^emical Co  
diameter: 3 angstrom) St. Louis, MO, USA 
MTT ； 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 414.3 Chemical Co., 
bromide; thiazolyl blue) (CisHieNgSBr) M. Louis, MU, U^A 
Non-fat milk / C卿ation，Nestle 
Penicillin-streptomycin , . . 
, .Ml- cAAA T^r/ 1 . • / GibcoBRL, Lite (penicillin: 5.000 U/ml protein / ^ , , • t 
streptomycin: 5000 g/ml) Technologies Inc. 
ou , USB (United States Phenol n … , . 1 � /n o n u \ 94.11 Biochemical), 
(C6H5OH) Cleveland, OH, USA 
Phosphoric acid , Sigma Chemical Co.,  
(H3PO4) St. Louis, MO, USA 
PIPES 202 4 Boehringer 
(piperazine-N,N-^j5(2-ethanesulfonic Acid)) ‘ Mannheim, Germany 
PMSF - Sigma Chemical Co., 
(phenylmethyl-sulfonyl fluoride) (C7H7FO2S) St. Louis, MO，USA 
Polyvinylpyrrolidone 如 議 Sigma Chemical Co., 
(PVP) ‘ St. Louis，MO, USA 
Potassium chloride ” Sigma Chemical Co., 
(KCl) St. Louis, MO, USA 
RPMI -j GibcoBRL, L i f e ~ 
(with phenol red) Technologies Inc. 
RPMI / GibcoBRL, Life 
(without phenol red) Technologies Inc. 
^ USB (United States 
‘ ( s o d i u m dodecyl sulfate) (CH3(CH.)nS0.Na) 288.38 匸丨已乂已^^ 。!^ !^^ 々 
Sodium chloride USB (United States 
^ 58.44 Biochemical), 
� ” Cleveland, OH, USA 
Sodium citrate ^g. , Sigma Chemical Co., 
(C6H5Na307-2H20) St. Louis，MO, USA 
Sodium dihydrogen phosphate 1 m Riedel-de Haen, AG, 
(NaH2P04) Germany 
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Sodium hydrogen phosphate U1 Q6 Sigma Chemical Co., 
(Na2HP04) St. Louis, MO, USA 
Sodium hydroxide � Sigma Chemical Co., 
(NaOH) St. Louis, MO, USA 
Sodium orthovanadate . ^ ^ g Sigma Chemical Co., 
(Na3V04) St. Louis, MO, USA 
Sorbitol Sigma Chemical Co., 
(D-Glucitol) (C6H14O6) St. Louis, MO, USA 
Sucrose Sigma Chemical Co.,  
(C12H22O11) St. Louis，MO, USA 
Tag DNA polymerase , GibcoBRL, Life 
(with lOX PGR buffer and 25 mM MgCb) ‘ 丁亡ol二gies Inc.  
or MBI, Fermantas 
TEMED 
(N, N, N,，N'-tetramethyl-ethylene diamine) 116.21 , , Boehrmger  
((CH3)2NCH2CH2N(CH3)2) Mannheim, Germany 
TNF-a ' ^ u V 
(recombinant murine tumor necrosis factor-alpha) o c � uiagnostics 
^ USB (United States 
12U4 c ^ g ) 勵 
Trypsin-EDTA GibcoBRL, Life 
(0.25% trypsin, 1 mM EDTA) Technologies Inc. 
Tween-20 Sigma Chemical Co., 
(polyoxyethylene-sorbitanmonolaurate) St. Louis, MO, USA 
X-Gal USB (United States 
5-Bromo-4-chloro-3-indolyl-b-D-galactopyranoside 408.6 Biochemical), 
(Ci4Hi5BrClN06) Cleveland, OH, USA 
Xylene cyanol FF ^^^ , Amersham Pharmacia  
(C25H27N206S2Na) - Biotech 
Cytochrome c 
Cytochrome c from different species were purchased from Sigma in powder form 
and stored at 4 °C. It is dissolved in distilled water, binding buffer or PBS according 
to the usage and stored at -20 
> 
Recombinant Murine TNF-a 
Recombinant murine TNF-a is produced by E. coli and purified by standard 
chromatographic techniques and has more than 95% purity as determined by 
SDS-PAGE (Manual of Roche Diagnostics). It was dissolved in PBS with the stock 
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concentration of 5 |ag/ml and was stored at -70 with minimal repeated freezing and 
thawing. It has the specific activity of more than 6.0 x 10^  U/mg. The unit definition is 
that one unit is defined as the amount of TNF-a required for mediating half-maximal 
cytotoxicity with L929 cells in the presence of actinomycin D. 
Antibodies for Western Blotting 
Primary antibody used was anti-cytochrome c (1:2000，recognizes 15 kDa 
protein) (clone number 7H8.2C12, Pharmingen). It was kept at 4 � C and repeated 
freezing and thawing were avoided. When the antibody was in use, it was diluted in 
5% (w/v) non-fat milk or 1 % (w/v) BSA in TBS-T. 
Other Chemicals 
Aprotinin, leupeptin, PMSF, ammonium persulfate, agarose, proteinase K, 
RNase A, ethidium bromide were used. Aprotinin and leupeptin were dissolved in 
dH20 and stored at -20 PMSF was dissolved in absolute ethanol and stored at -20 
Ammonium persulfate was dissolved in dH20 and stored at 4 Agarose was 
dissolved in TBE buffer. Ethidium bromide solution was diluted with dHiO and kept 
at room temperature in dark. Proteinase K and RNase A were dissolved in dH^O and 
TE buffer respectively and kept at -20 
2.1.2. Buffers 
I 
Buffer was prepared by dissolving chemicals in distilled water (dHiO) and 
titrated to suitable pH with either HCl or NaOH, unless otherwise specified. 
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2.1.2.1. Buffers commonly used 
Binding Buffer was prepared with 10 mM HEPES, 75 mM NaCl, 5 mM MgCb, 
1 mM CaCl2. The pH was then adjusted to 7.4 and the buffer was stored at room 
temperature. 
Elution Buffer was prepared with 20 mM Tris-acetate, 4 M guanidine 
thiocyanate. The pH was then adjusted to 8.3 and the buffer was stored at room 
temperature, 1 mM DTT was added before used. 
Phosphate buffered saline (PBS) was prepared using 2.7 mM KCl, 1.5 mM 
KH2PO4, 136 mM NaCl and 8 mM Na2HP04 and the pH was adjusted to 7.4. PBS 
was made sterilized by autoclave and was then stored at 4 
2.1.2.2. Reagent for molecular work 
6X loading buffer was prepared with 0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol FF and 40% (w/v) sucrose and the buffer was stored at 4 °C. 
TE buffer was prepared with 10 mM Tris and 0.5 mM EDTA. The pH was then 
adjusted to 7.4. The buffer was sterilized by autoclave and was then stored at room 
temperature. 
) 
5X TBE buffer was prepared form the pre-weighed and pre-mixed powder 
purchased from USB. The powder was reconstituted to a 5X TBE solution by adding 
dH20 to 400 ml. After reconstitution, the 5X solution is: 0.445 M Tris, 0.445 M boric 
aid and 0.01 M EDTA-Na4. The 5X TBE buffer was stored at 4°C. 
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2.1.3. Bacterial culture 
Medium of bacterial culture 
LB and SOB were purchased in pre-mixed powder form. After dissolved in 
distilled water and autoclaved, the medium were stored at 4 Suitable antibiotic 
was added before used. 
LB plate 
LB plate was prepared by 20 g/L LB, 1.5% agar in distilled water. After 
autoclaving and cooling to 55 °C，ampicillin was added to a final concentration of 50 
^ig/ml. Plates were then filled and stored at 4 °C until use. 
2.1.4. Culture of cell 
2.1.4.1. TNF-a Sensitive Cell Line, L929 
L929 cells were purchased from American Type Culture Collection (ATCC, 
Rockville, MD, USA) and they are TNF- a sensitive cell line. They were established 
from the subculture generation of the parent L strain of fibroblasts in the C3H/An 
mouse. They have adherent characteristics and were maintained in RPMI 1640 
medium supplemented with 10% (v/v) fetal bovine serum and 1% 
penicillin-streptomycin (v/v) (complete medium) at 37 °C, 5% CO2 incubator (SHEL 
LAB) with humidified atmosphere. 
I 
2.1.4.2. Medium of cell culture 
RPMI 1640 (Phenol Red Medium) 
RPMI (Rosewell Park Memorial Institute) 1640 was the medium used for 
cultimng of TNF-a sensitive cell line. It consisted of phenol red, L-glutamine and 0.5 
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mM HEPES. The power of RPMI was then dissolved in one liter of dHaO and was 
supplemented with 24 mM NaHCOs. The pH of the medium was adjusted to 7.4. 
Then, the medium was sterile filtered with a 0.22 |xm cellulose acetate membrane 
bottle-top filter (7111，Falcon, Becton Dickinson, NJ, USA). The medium was then 
supplemented with 10% FBS (v/v) and 1% penicillin-streptomycin (v/v) for cell 
culture. The medium was stored at 4 °C. 
RPMI 1640 (Phenol Red-free Medium) 
Phenol red-free RPMI medium consisted of L-glutamine without phenol red or 
HEPES. The powder of phenol red-free RPMI was then dissolved in one liter of dHzO 
and was supplemented with 24 mM NaHCOs and 25 mM HEPES. The pH of the 
medium was adjusted to 7.4. Then, the medium was sterile filtered with a 0.22 |im 
cellulose acetate membrane bottle-top filter. The colorless medium was supplemented 
with 1% penicillin-streptomycin (v/v) only. The medium was then stored at 4 °C. 
2.1.5. Reagent for Western blotting 
2.1.5.1. Protein extraction 
Lysis buffer for total protein extraction was prepared with 1 mM Na3V04, 1% 
(w/v) SDS, 10 mM Tris. The pH was then adjusted to 7.4 and stored at room 
temperature. Prior to the lysis of cells, the lysis buffer was supplemented with 5 mM 
MgCl2, 1 mM PMSF and protease inhibitors such as 21 fig/ml aprotinin and 5 |_ig/ml 
) 
leupeptin. 
Lysis buffer for cytochrome c extraction was prepared with 75 mM NaCl, 1 
mM NaH2P04, 8 mM NazHPO*, 250 mM sucrose. The buffer was stored at 4 Prior 
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to the lysis of cells, the buffer was supplemented with 1 mM PMSF, 21 |ig/ml 
aprotinin, 5 |ag/ml leupeptin and various concentrations of digitonin. 
2.1.5.2. SDS-PAGE 
4X lower gel buffer was prepared with 1.5 M Tris base and 14 mM SDS. The 
pH of the buffer was adjusted to 8.8 and stored at 4 
4X upper gel buffer was prepared with 0.5 M Tris base and 14 mM SDS. The 
pH of the buffer was adjusted to 6.8 and stored at 4 
15% separating . gel buffer was freshly prepared with 50% (v/v) 
acrylamide/bis-acrylamide (30%) solution, 25% (v/v) 4X lower gel buffer, 0.05% 
(w/v) ammonium persulfate and 0.12% (v/v) TEMED. 
4.5% stacking gel buffer was freshly prepared with 15% (v/v) 
acrylamide/bis-acrylamide (30%) solution, 25% (v/v) 4X upper gel buffer, 0.07% 
(w/v) ammonium persulfate and 0.13% (v/v) TEMED. 
2X SDS loading buffer was prepared with 2% (w/v) SDS, 10% (w/v) sucrose, 
0.002% bromophenol blue and 62.5 mM Tris. The pH of the buffer was adjusted to 
6.8. Buffer was supplemented with 5% (v/v) 2-mercaptoethanol and stored at 4 
I 
SDS tank buffer was prepared with 25 mM Tris base, 192 mM glycine and 
0.1% (w/v) SDS and stored at room temperature. 
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Commassie Blue staining solution for protein staining was prepared with 
acetic acid, methanol and dHiO with a ratio of 1:3:10. 0.05% (w/v) commassie 
brilliant blue R-250 was added and the solution was stored at room temperature. 
De-stain solution for removing commassie brilliant blue R-250 was prepared 
with 40% (v/v) methanol and 10% (v/v) acetic acid and was stored at room 
temperature. 
2.1.5.3. Electro-blotting 
Electroblot buffer was freshly prepared with 48 m M Tris base, 39 m M glycine, 
20% (v/v) methanol and 0.0375% (w/v) SDS. The pH of the buffer was adjusted to 
9.2 to 9.4. 
TBS-Tween-20 (TBS-T) was prepared with 10 m M Tris base, 0.15 M NaCl and 
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2.2. Methods 
2.2.1. Conjugation of protein to solid support 
2.2.1.1. Conjugation of protein on PVDF membrane 
The dry 0.22 }xm PVDF (polyvinylidene fluoride) membrane ( I m m o b i l o n - p S Q , 
Millipore) was rehydrated with absolute methanol and then immersed in PBS for 15 
min. After removing the excess PBS by kimwipes, the membrane was placed on 
kimwipes. Then cytochrome c in PBS was dropped on the membrane and the 
cytochrome c was conjugated on the membrane after the solution was soaked through 
the membrane. 
2.2.1.2. Conjugation of protein on Sepharose 
N-Hydroxysuccinimidyl-Agarose (Sigma) was used as solid support and was 
first packed in column. The isopropanol as stock buffer of the Sepharose was washed 
out with 1 m M ice-cold HCl and then 5 mg/ml cytochrome c in coupling buffer ( 0.2 
M NaHCOa, 0.5 M NaCl, pH 8.3 ) was loaded and incubated for 30 minutes at room 
temperature. After that, the uncoupled cytochrome c was washed away with the 
coupling buffer and the excess active groups of the solid support that have not 
coupled to the ligand were deactivated by buffer A ( 0.5 M ethanolamine, 0.5 M NaCl, 
�� 
pH 8.3 ) and buffer B ( 0.1 M acetate, 0.5 M NaCl, pH 4.0 ) alternatively for 3 cycles. 
The column was finally washed with PBS and stored at 4 °C in PBS. 
» 
2.2.1.3. Conjugation of protein on magnetic bead 
Before conjugation of cytochrome c, the magnetic beads (Dynabeads M-280 
Tosylactivated) were resuspended well and washed once with Buffer A (0.1 M 
Na-phosphate buffer, pH 7.4, 0.019 M Na H2PO4 and 0.081 M Na�HPO4). Then 3 pg 
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cytochrome c was added per 10^  magnetic beads (approximately 20 |ag/mg). After 
resuspended the Dynabeads thoroughly, a final concentration of 1-2 x 10^ beads per 
ml coating solution was resulted. The coating mixture was incubated for 16-24 hr at 
37 °C with slow tilt rotation. 
After incubation, the supernatant was removed and the magnet beads were 
collected. The beads were then washed four times with two times in Buffer C (PBS, 
pH 7.4 with 0.1% (w/v) BSA) for 5 minutes at 4 °C, once in Buffer D (0.2 M Tris, pH 
8.5 with 0.1% (w/v) BSA) for 24 hr at 20 °C or for 4 hr at 37 °C and the last time in 
Buffer C for 5 minutes at 4 °C. Then the magnetic beads were cytochrome c 
conjugated and were ready for use. The unused cytochrome c conjugated beads were 
stored in Buffer Cat 4 
2.2.2. SELEX 
2.2.2.1. Selection 
Before selection, the oligonucleotide pool was first heated in binding buffer at 95 
for 3 minutes. And then, the heated oilgonucleotide pool was incubated with the 
protein conjugated solid support in binding buffer for various times at various 
temperatures as indicated. Then the solid support was collected and washed with 
binding buffer for several times. The unbound oligonucleotides were washed away 
and the bound oligonucleotides were then eluted with elution buffer or by excess 
ligand in binding buffer, fhe elute collected was then extracted with phenol: isoamyl 
alcohol in equal volume and precipitated with 100% ethanol in the presence of 1/10 
volume 3 M sodium acetate (pH 5.5) and 25 ^ ig of glycogen at -20 The precipitate 
was collected with centrifugation at 20,812 x g (14,000 rpm, 9.5 cm, Eppendorf 
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Centrifuge 5417R) for 20 mins at 4 The pellet collect was then washed with 
ice-cold 70% ethanol and another centrifugation at 20,812 x g (14,000 rpm, 9.5 cm, 
Eppendorf Centrifuge 5417R) for 20 mins at 4 °C. The precipitate was then dried in 
air or oven and then dissolved in autoclaved distilled HiO. 
2.2.2.2. Photo-selection 
Production of Photo-oligonucleotide pool 
PCR was done to incorporate dBrUTP into the oligonucletoides. In 1.5 ml 
reaction in standard Tag P C R buffer including 1.5 m M MgCh, 30 pmol templates was 
added with 200 |liM each ofdATP, dGTP, dCTP and dBrUTP and 300 n M of forward 
and reverse primers which are complementary to the flanked end of the 
oligonucleotides. The reaction mixture was heated at 95 °C for 3 minutes before 
adding 18.75 units of Tag and 18.75 units of Pwo. After enzymes were added, P C R 
was preformed for 16 cycles of 95 for 40 sees, 55。C for 1 min and 72 °C for 2 
mins and finally terminated with 72 °C for 10 mins. 
The P C R product was then concentrated by using Microcon YM-30, regenerated 
cellulose 30,000 M W C O (Amicon, Millipore Corporation, Bedford, M A ) and eluted 
with 50 fil dH20. Polyacrylamide (12%) with 7 M urea denaturing gel was then run to 
confirm the size and also purify the photo-oligonucleotide pool from the excess 
deoxynucleotide and the enzymes. 
I 
The band in suitable size was cut and then crashed. Binding buffer was added 
and incubated with the crashed gel at 37 °C overnight with rotation. The solution was 
then separated from the gel by using multispin separation column (Axygen 丁m 
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Scientific, California, USA) and absorbance at 260 nm was measured to qualify the 
amount of oligonucleotide pool in the solution. 
Photo selection 
The photo-oligonucleotide pool in final concentration of 50 n M was incubated 
with target ligand in a final concentration of 1.5 n M in a total volume of 800 \i\ for 15 
mins at room temperature with gently shaking. After incubation, the solution was 
irritated by U V light from U V / White light transilluminator (Spectroline, model 
TVD-IOOOR) for 2 mins. The solution was then collected and filtered by using 
Microcon YM-30, regenerated cellulose 30,000 M W C O (Amicon, Millipore 
Corporation, Bedford, MA). All the bound aptamer-ligand complex, free ligand and 
free oligonucleotide remained on the filter and were then eluted by dH20. The eluate 
was then mixed with 0.2 volume of 6X loading buffer and 0.2 volume of 7 M urea and 
heated at 95 °C for 3 minutes. The bound and unbound oilgonucleotides were then 
separated by 12% polyacrylamide with 7 M urea denaturing gel. After staining with 
ethidium bromide and visualized by U V light厂the band run slower in the gel were cut 
and crashed. TE buffer with 400 ^ig/ml proteinase K was added and incubated with 
the crashed gel at 37 overnight with rotating. The eluted aptamer were then 
collected and extracted with phenol xhromoform. After precipitated with ethanol, 




P C R was performed with the aptamer selected. Various amount of aptamer was 
gently mixed with 2.5 ^ il of lOX P C R buffer (final conc. of IX)，1.5 of 25 m M 
MgCl2 (final conc. of 1.5 mM), 0.5 \i\ of 10 m M dNTP mix (final conc. of 0.2 mM), 
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0.5|al of 300 |iM forward primer (for single strand PCR, final conc. of 6 |aM) or 10 
|aM forward primer (for double stand PCR, final conc. of 0.2 |iM) and 0.5 of 10 
\xM of reverse primer (final conc. of 0.2 jiM), 0.25 of Tag D N A polymerase (5 
units/|il, final conc. of 1.25 units/25 fil) and added up the total volume to 25 )al with 
autoclaved dHsO. P C R was then performed with the following conditions. 
Table 2.2 Summary of P C R condition. 
Conditions Temperature Time Number of cycles 
Initial denaturation 95 3 min 1 
Denaturation 95 45 sec . , ^ 
A V FToT^ ^ various number of 
Annealing 55 C 30 sec , 
Elongation 72 1 min 30 sec  
Final elongation 72 10 min • 1 
2.2.3. Separation of oligonucleotides 
2.2.3.1. Separate short length double-stranded oligonucleotides by using 
polyacrylamide gel 
The apparatus of Mini-Protean II cell (BIO-RAD Laboratories) for SDS-PAGE 
was set up according to the manual. 
Polyacrylamide (12%) separating gel in 0.5X TBE buffer was used. For each 
sample, 1 volume of D N A sample was mixed with 1/5 volume of 6X D N A loading 
buffer. Then, D N A samples, together with the suitable D N A markers were loaded on 
» 
each well. The voltage was set at 200 V and protein samples were run for about 45 
minutes. After that, gels were removed from the apparatus and were soaked in 
ethidium bromide. 
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Fig. 2.1. Double-stranded PCR products separated by native 
polyacrylamide gel. 
After P C R amplification, the products were mixed with 1/5 volume of 6X 
D N A loading buffer and then loaded into wells. After separation by 12% 
polyacrylamide gel, D N A was stained with ethidium bromide and 
visualized under U V light. D N A ladder (25 bp, 0.4 |ig) was used as size 
marker. 
2.2.3.2. Separate short length single-stranded oligonucleotides by using 
denaturing polyacrylamide gel 
The apparatus of Mini-Protean II cell (BIO-RAD Laboratories) for SDS-PAGE 
was set up according to the manual. 
To separate single-stranded D N A , 12% polyacrylamide with 7 M urea separating 
gel in 0.5X TBE was used. For each sample, 1 volume of D N A sample was mixed 
with 1/4 volume of 6X D N A loading buffer and 1/4 volume of 7 M urea. Then the 
I 
mixture was heated at 95°C for 3 minutes. D N A samples, together with the suitable 
D N A markers were loaded on each well. The voltage was set at 200 V and D N A 
samples were run for about 45 minutes. After that, gels were removed from the 
apparatus and were soaked in ethidium bromide. 
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M -ve PGR products 
M primer 
Fig. 2.2. Single-stranded PGR products separated by denaturing 
polyacrylamide gel. 
After PCR amplification, the products were mixed with 1/4 volume of 6X 
D N A loading buffer and 1/4 volume of 7 M urea. The mixtures were heated 
at 95 °C for 3 minutes and then loaded into wells. After separation by 12% 
polyacrylamide gel with 7 M urea, the D N A were stained with ethidium 
bromide and visualized under U V light. Ten pmol of pool of the 
oligonucleotides were used as marker (M). PCR amplification without any 
oligonucleotides added (-ve). 
2.2.3.3. Extract the DNA from polyacrylamide gel 
After cutting the band containing the suitable size of D N A , the gel was stored in 
a pre-weighed microfuge tube. The gel band with the tube was then weighed and the 
net weight of the gel band was then calculated. After dring the gel band in oven, it was 
then crashed into powder. Binding buffer in 2X volume of the gel band was added to 
the crashed gel and incubated at 37。C for overnight or 70 °C for 3 hours. 
The solution with D N A eluted was then separated from the gel by using multi 
spin separation column (Axygen tm Scientific, California, USA) and the amount of 
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oligonucleotide pool in the solution was then qualified by measuring the absorbance 
at 260 nm. 
2.2.3.4. Estimate the amount of DNA in solution after extraction 
The amount of D N A in solution was estimated by measuring absorbance at 260 
nm. For O.D.260 = 1，there should be 33 jig single stranded D N A or 50 |ig double 
strand D N A in 1 ml solution. 
Concentration of single stranded D N A (mol/|il) = ~。•仅•腕 x 33x10 ^joOO 
MolecularweightoftheDNA 
Concentration of double stranded D N A (mol/|il) = ~ + j 000 
MolecularweightoftheDNA 
2.2.3.5. Agarose Gel Electrophoresis 
Agarose gel electrophoresis is used to separate D N A and R N A according to their 
molecular weight under electric field. 
One percent agarose gel was prepared by dissolving the agarose powder in IX 
TBE buffer in the flask. The flask was then weighed and was put into the microwave 
oven to heat for 1 min until the agarose dissolved. The mixture was then cooled to 
around 50 and was poured into the cassette until the agarose formed the gel like 
structure. 
The D N A was then run in agarose gel at constant voltage. After electrophoresis, 
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the gel was stained with ethidium bromide for 10-20 min, followed by destaining in 
dH20 for another 10-20 min. The gel was then put onto the U V / White light 
transilluminator (Spectroline, model TVD-IOOOR). 
2.2.4. Cloning of selected polyclonal aptamer 
2.2.4.1. Restriction cutting 
For restriction cutting of the plasmid or aptamer, 1 [ig of D N A was mixed with 1 
1^1 restriction enzyme, in a final volume of 20 ^ il of IX restriction buffer. The reaction 
was preformed at 37 °C for 2 hours and heat inactivated at 65 °C or 80 °C for 20 
minutes. 
2.2.4.2. Ligation 
In a 10 |Lil ligation reaction system, it consists of 1 |j,l T4 ligase, 1 ^il lOX ligase 
buffer and a total of 500 ng D N A . The vector and insert were in 1:4 ratios. The 
reaction was preformed at 16 °C overnight. 
2.2.4.3. Preparation of competent cells 
Bacterial cell was first incubated in 2 ml LB with shaking at 37 °C overnight. 
After that, the bacterial culture was added to 100 ml LB medium and shaking at 37 °C 
until absorbance at 550 nm reached 0.48. The bacterial culture was then iced for 15 
minutes and pentrifuged at 4,000 g for 5 minutes. 0.4 volume of Tfb I solution (30 
m M potassium acetate, 100 m M rubidium chloride, 10 m M calcium chloride, 50 m M 
manganese chloride, 15% (v/v) glycerol, pH 5.8, with dilute acetic acid) was added to 
resuspend the pellet. The suspension was then iced for another 15 minutes and 
centrifuged at 4,000 g for 5 minutes. 0.04 volume of Tfb II (10 m M MOPS, 75 m M 
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calcium chloride, 10 m M rubidium chloride, 15% glycerol, pH 6.5, with dilute sodium 
chloride) was added to resuspend the pellet. After keeping the bacteria in an ice bath 
for 15 minutes, the competent cells can be used immediately or quick freeze at -70 
The competent cells should be stored in small amount per tube and thaw and freeze 
should be avoided. 
2.2.4.4. Transformation of plasmid into competent cell 
At the bottom of a cap tube in ice, 5 \i\ of the ligation product was mixed with 50 
}il competent cells. The tube was then kept in ice for 30 minutes and was transferred 
to a water bath per-heated at 43 °C for exactly 90 seconds. After heat shocked, the 
tube was then placed in jce for another 2 minutes. Pre warmed LB (1 ml) was then 
added to the tube and the tube was warmed in a 37 water bath for 45 - 60 minutes. 
The bacterial culture was then centrifuged at 5,000 r.p.m. for 5 minutes. The 
supernatant was discarded and 100 [i\ of LB was added to resuspend the pellet. All the 
bacteria were transferred to and spread evenly on a LB plate with suitable antibiotics. 
The plate was then incubated at 37 overnight. 
2.2.4.5. Plasmid extraction from bacterial culture 
Bacteria colony was picked and incubated in 2 ml of LB with suitable antibiotics 
at 37 overnight with shaking. 1.5 ml bacterial culture was transferred to a 
microfuge tube and centrifuged at 20,800 x g (14,000 rpm, 9.5 cm, Eppendorf 
I 
Centrifuge 5417R) for 30 seconds. The supernatant was then removed thoroughly. 
One hundred ice-cold Alkaline Lysis Solution I was then added to resuspend the 
pellet. After vigorous vortexing, 200 \i\ freshly prepared Alkaline Lysis Solution II 
was added and mixed thoroughly without vortexing. Alkaline Lysis Solution (150 \i\) 
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III was then added. The tubes were inverted several times and stored in ice for 5 
minutes. The lysate was then centrifUged at 20,800 x g (14,000 rpm, 9.5 cm, 
Eppendorf Centrifuge 5417R) for 5 minutes at 4 The upper layer was then 
transferred to a new microfuge tube and extracted once with phenol xhloroform and 
once with chloroform. The plasmid was then precipitated by ethanol and washed once 
by 70% ethanol. The pellet was then dried and dissolved in 50 fal TE buffer. 
2.2.5. Cell culture 
2.2.5.1. Cell culture of L929 
Generally, L929 cells were kept in 25, 75 or 125 cm^ culture flasks and passages 
were made every 3 or 4 days after growing to confluence. In each passage, the spent 
medium was discarded. Cells were then washed with PBS once and trypsinized from 
the culture flask. Complete medium was then added and cells were collected. 
Centrifugation was carried out at 453 x g (1,500 rpm, 16.0 cm, Eppendorf Centrifuge 
581 OR) for 3 min. Cells pellet was then resuspended in complete medium and 
transferred to a new culture flask. 
2.2.5.2. Preservation of cells 
Frozen stock of cells were kept in freezing mixture and stored in liquid nitrogen. 
Cells trypsinized from culture flasks were resuspended with complete medium. 
Centrifugation was then carried out at 453 x g (1,500 rpm, 16.0 cm, Eppendorf 
Centrifuge 581 OR) for 3 min. Cells (5 x 10^) were resuspended in one ml freezing 
mixture. The freezing mixture composed of 50% FBS (v/v), 40% complete medium 
(v/v) and 10% D M S O (v/v). Cell suspension (1 ml) was transferred to the freezing 
vials. The cells were then cooled to -20 °C until frozen and vials of cells were then 
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kept at -70 °C overnight. Afterwards, cells were stored in liquid nitrogen until use. 
To thaw the cells, cells were thawed quickly and diluted in excess pre-warmed 
complete medium. Centrifiigation at 453 x g (1,500 rpm, 16.0 cm, Eppendorf 
Centrifuge 581 OR) for 3 min was then carried out and pellet of cells was suspended 
into complete medium and cells were transferred to a new culture flask. 
2.2.5.3. Treatment with TNF-a 
Cells (1 X lOVml) in complete medium were seeded on 6-well plates at 37 °C and 
5 % CO2 overnight. On the day of experiment, cells were washed with serum-free 
medium twice. Cells were then treated with TNF-a (50 ng/ml) for various time 
intervals. Control cells were only treated with serum-free medium alone. After 
treatment, cells were collected for different assays. 
2.2.5.4. Fixation of cell 
L929 cells (2.5 x 10^) were seeded in 24-wells plates in complete medium and 
incubated at 37 and 5 % CO2 overnight. The cells were then washed with PBS 
twice. Glutaraldehyde (0.3%) in PBS (1 ml) was added to each well and incubated for 
10 minutes at room temperature. The cells were then washed with PBS two more 
times. Triton X-100 (1%) in PBS (1 ml) was then added and mixture was incubated 
for 15 minutes at room temperature. After washed twice with PBS, non-specific 
» 
blocking was done by incubating the cells with 1% B S A in PBS at 4 overnight. On 
the next day, the cells were washed with PBS for two more times and then stored in 
PBS at 4 until used. 
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2.2.6. Western blotting analysis 
2.2.6.1. Preparation of proteins from cells 
Cellular proteins can be isolated with the use of digitonin of various 
concentrations. L929 cells with appropriate treatments were washed with serum-free 
medium twice and then trypsinized. After centrifugation, the cell pellet was washed 
with serum-free medium twice and the number of cells was then counted. In each 
sample, 50 |il of lysis buffer (75 m M NaCl, 1 m M NaH2P04, 8 m M Na2HP04, 250 
m M sucrose, 21 |ag/ml aprotinin, 5 |ig/ml leupeptin, 1 m M PMSF and various 
concentrations of digitonin) was added to 4 x 10^ cells and the mixture was vortex 
vigorously for 30 seconds at room temperature. After that, samples were centrifuged 
at 10,621 X g (10,000 rpm, 9.5 cm, Eppendorf Centrifuge 5417R) for 1 min at room 
temperature with a centrifuge (MSE, MicroCentaur, Sanyo). Subsequently, 
supernatant was then collected and 50 of 2X SDS loading buffer was added. The 
mixture was then boiled for 10 min and centrifugation was then carried out at 20,817 
X g (14,000 rpm, 9.5 cm, Eppendorf Centriftige 5417R) at 4 for 7 min. After that, 
the supernatant was collected and the cell lysate was stored at -70 
2.2.6.2. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The apparatus of Mini-Protean II cell (BIO-RAD Laboratories) for SDS-PAGE 
was set up according to the instruction. 
» 
SDS polyacrylamide separating gel (15%) and 4.5% stacking gel were used. In 
each experiment, 20 \i\ of cell lysate was boiled for 5 min before used. Then, protein 
samples, together with the low range protein marker were loaded on each well. The 
voltage was set at 150 V and protein samples were run for 1.25 hr. After that, gels 
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were removed from the apparatus and were soaked in electroblot buffer. 
2.2.6.3. Electroblotting of protein 
The electroblotting of proteins was carried out with the use of the Mini 
Trans-Blot Cell (tank transfer system, BIO-RAD Laboratories). 
Prior to the electroblotting, the dry 0.22 |im PVDF (polyvinylidene fluoride) 
membrane (Immobilon-P^^, Millipore) was rehydrated with absolute methanol and 
then immersed in electroblot buffer for 15 minutes. Moreover, 1 m m filter paper 
(Whatman) was also soaked in electroblot buffer before use. The tank transfer system 
for electroblotting was set up with the following sequence: cathode, fiber pad, 3x filter 
paper, gel, P V D F membrane, 3x filter paper, fiber pad and then anode. Electroblotting 
was then performed with the voltage of 100 V for 1 hr. 
After electroblotting, the gels were stained with commassie blue staining solution 
overnight for protein determination and then de-stained with de-stain solution for 
another day. 
2.2.6.4. Probing antibodies or aptamers for proteins 
After blotting, the membrane was transferred to a petri dish and 20 ml of 1% 
(w/v) B S A or 5 % (w/v) non-fat milk in TBS-T or binding buffer was added and » 
incubated at 4 overnight for non-specific blocking. After that, the membrane was 
washed with TBS-T or binding buffer twice for 15 min. The membrane was probed 
with primary antibody or aptamer for 1 hr at room temperature with rotations. The 
antibody or aptamer was then removed and the membrane was washed with TBS-T or 
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binding buffer twice for 15 min for three times. H R P conjugated anti-mouse antibody 
or streptavidin H R P conjugated antibody was then loaded to the membrane for 
another hour. After that, the membrane was washed with TBS-T or binding buffer for 
15 mins for three times also. 
2.2.6.5. Enhanced chemiluminescence (ECL) Assay 
ECL assay was performed by mixing the ECL reagent 1 and reagent 2 in a ratio 
of 1:1 (Amersham Pharmacia Biotech). The membrane was then exposed to the ECL 
reagent mixture for 1 min at room temperature. After that, the membrane was wrapped 
with Saran wrap and was developed on Fuji Medical x-ray film (super Rx, Fuji) at 









In this project, we were trying to select an aptamer that can bind cytochrome c 
specifically with high affinity. To start the selection, 3-APT, a pool of 
oligonucleotides containing 40 random nucleotide sequences was used. 
3.1 Selection of aptamer against cytochrome c dotted on 
membrane with counter selection against BSA also on 
membrane. 
3.1.1 Selection process 
To start the first selection, 100 pmol of the oligonucleotides were used. The 
oligonucleotides were heated at 95 for 3 minutes in binding buffer to unfold their 
secondary and tertiary structures and let them refold into their unique 
sequence-dependent structures. After refolding, the pool was first counter selected 
against 1% (w/v) B S A coated on a P V D F membrane. By this counter selection, 
oligonucleotides that bind to the solid support or the blocking agent B S A were 
eliminated. Oligonucleotides remained were then selected against cytochrome c (1 
|ig) coated on another P V D F membrane. After several rounds of washing with 
binding buffer, the oligonucleotides bound to the target were eluted by the elution 
buffer at 90 °C for 10 minutes. The oligonucleotides were then extracted with phenol: 
chloroform: isoamyl alcohol (v:v:v = 25:24:1) and precipitated with ethanol. The 
oligonucleotides collected were then amplified by P G R with primer pair which is 
.complementary to the flanked ends of the oligonucleotides. The amount of 5， 
» 
forward primer was 30 times more than that of the 3' reverse primer to produce more 
the single-stranded sense oligonucleotides. The PCR products were then subject to 
the second round of selection. 
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3.1.1.1 PCR cycles 
After the selection of oligonucleotides against cytochrome c, oligonucleotides 
were amplified by PCR. Before starting the PCR, the optimal number of 
amplification should be determined. Theoretically, the PCR cycle number is mostly 
restricted in the range of 15-25. This is because after the optimal number of cycles of 
PCR, product of the suitable size will be saturated and high molecular PCR products 
will be further amplified during the excess PCR cycles. To eliminate this artifact, the 
optimal cycle number for PCR was investigated. 
In a final 50 i^l PCR reaction mixture, 1 pmol of oligonucleotides was added 
and P C R performed. Started from cycle 10, 10 [d of the reaction mixture was 
collected for every 5 cycles until cycle 30. The reaction mixtures were then separated 
by a 12% polyacrylamide 7 M urea denaturing gel (Fig. 3.1). 
From the results, it can be seen that the amount of high molecular weight 
product increased with the number of P C R cycle. However, the intensity of the band 
of oligonucleotides with the size of 76 bp did not increase much when the cycle 
number was beyond 15. These results suggest that 15 cycles was the optimal number 
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Fig. 3.1. A denaturing gel showing the P C R products from different cycle 
numbers. 
Oligonucleotides (1 pmol) were added to a P C R reaction mixture (final 
volume 25 |LI1). Thirty cycles of amplification were performed. Ten pi of 
the P C R products were collected from the mixture after cycle 10, 15, 20, 
25, and 30. The products were then mixed with 2.5 jil urea (7M) and 2.5 
6X loading buffer. After heated at 95 for 3 minutes, the mixtures and 
10 pmol oligonucleotides of size 76 bp were loaded to the well of 12% 
polyacrylamide with 7 M urea denaturing gel as indicated. After separation, 




3.1.1.2 Polyclonal aptamer 
After several rounds of selection, the selected aptamers should be polyclonal 
(i.e. carry different sequences in the core fragment). They were first tested by dot 
blot analysis. Various amounts of cytochrome c were dotted on PVDF membrane and 
non-specific blocking was done by 1% (w/v) BSA. The cytochrome c on the 
membrane were then labeled with the aptamers selected. To generate signals, the 
aptamers selected were amplified by P G R with excess biotinylated 5' forward primer 
in the last round of amplification. The single stranded sense aptamers so produced 
were biotinylated which could be recognized by streptavidin. After labeling and 
washing, streptavidin with H R P conjugated and suitable substrates were added and 
bioluminescent signals were generated and detected by X-ray films. Our results 
indicate that streptavidin HRP at 5000-fold dilution was too strong (i.e. too dark) 
while dilution of 10000-fold was the optimal concentration (data not shown). 
Results below showed that the polyclonal aptamers selected could label 
cytochrome c in a dose-dependent manner (Fig. 3.2). In this Western blot, 0.5 [ig of 




Fig. 3.2. Binding of polyclonal aptamers with cytochrome c by dot plot 
hybridization. 
Cytochrome c of various amounts were dotted on a P V D F membrane with 
1% (w/v) B S A as a non-specific binding blocker. The membrane was then 
labeled with polyclonal aptamers (1:400) for 1 hour and then incubated 
with streptavidin conjugated H R P antibody (1:10000) for another hour in 
binding buffer with 1% (w/v) BSA. ECL assay was performed and signal 





3.1.1.3 Monoclonal aptamer 
The polyclonal aptamers selected in the previous chapter should have different 
sequences in the core region. After confirming the polyclonal aptamers that could 
bind with cytochrome c, monoclonal aptamers were produced by cloning them into 
pBlueScript II vectors. 
Briefly, the aptamers were first amplified by PCR with equal concentration of 
forward and reverse primers to produce double-stranded oligonucleotides. As there 
were two recognition sites of restriction enzymes Hind III and Eco RI in the 5' and 3' 
primer ends of the oligonucleotide respectively, aptamers and pBlueScript II vector 
were first incubated separately with the two enzymes (1^1 each for 1 |ig D N A ) at 37 
for 2 hours for the restriction cutting and at 65 °C for 20 minutes to inactivate the 
enzymes. One percent agarose gel was then used to purify the vector and 12% 
polyacrylamide gel for the aptamers after reaction. The vectors and aptamers eluted 
from the gels were then incubated together in a molar ratio of 1:4 with T4 ligase at 
16 overnight for ligation. 
After ligation, the plasmids that contained the aptamers were transformed into 
competent bacterial cells by heat shock at 43 The transformed competent 
‘ bacterial cells were then allowed to grow on LB ampicillin agar plates. Since a 
) 
bacterial colony is grown from a single cell, cells in a single colony should contain a 
single plasmid with a unique insert and the antibiotic resistance property. 
Subsequently, bacterial cells were collected from a single colony and culture in LB 
brooth for overnight at 37 °C. Plasmids were then isolated by alkaline lysis method 
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buffer. After purifying the plasmid from the bacterial culture of a single colony, 
monoclonal aptamer was amplified again from the plasmid by P C R (Fig. 3.3). 
After these cloning steps, 10 monoclonal aptamers were obtained. However, 
from the result of the P C R products separated by denaturing gel (Fig. 3.3), one of the 
clones was discarded (marked with F) as it contained a high and a low molecular 
weight products after P C R amplification. Only 9 clones were left and were named as 
cy-1 to cy-9. After amplification, aptamers cy-1 to cy-9 were tested for the binding. 
一 76bp 
25 bp Cy-1 2 3 4 5 6 F 7 8 9 
marker 
Fig. 3.3. A denaturing gel showing the P C R products amplified from 10 
monoclonal plasmids. 
One |Lil of 100-fold diluted plasmids extracted from different colonies were 
added individually to a P C R reaction mixture (final volume 25 jil). Thirty 
cycles P C R were performed. The P C R products were then mixed with 
6.25 III urea (7M) and 6.25 ^ il 6X loading buffer. After heated at 95 °C for 
3 minutes, the mixtures and the 25 bp marker were loaded to the wells of 
12% polyacrylamide with 7 M urea denaturing gel. After separation, D N A 
bands were visualized by U V with ethidium bromide. The lane marked 
with 'F' was discarded and the others were named as cy-1 to cy-9. 
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3.1.2 Binding test of cy-1 to cy-4 to cytochrome c 
After obtaining the 9 monoclonal aptamers, aptamers cy-1 to cy-4 were tested 
for the binding to cytochrome c by using cytochrome c conjugated Sepharose. The 
cytochrome c on the Sepharose were first labeled with aptamers for 15 minutes at 
room temperature. After washed with binding buffer, the biotin on the aptamers were 
recognized by streptavidin with HRP conjugated. O P D (0.8 mg/ml) in substrate 
buffer with 0.03% H2O2 was then added as the substrates for HRP, and the reaction 
was stopped by O.IM sulfuric acid. Yellowish products were measured at O D 492 
nm. 
The results of the binding test are shown in Fig. 3.4. From the graph, aptamers 
cy-1 to cy-4 were found to bind to cytochrome c when compared to the negative one 
which had no aptamer added. Among the four aptamers tested, cy-3 was shown to 
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Fig. 3.4. Binding of aptamers cy-1 to cy-4 with cytochrome c conjugated 
on Sepharose. 
Cytochrome c conjugated Sepharose (20 |il) was incubated with 50 |il 
P C R products of cy-1 to cy-4 amplified from plasmid in 400 |xl binding 
buffer or binding buffer only (negative) (total volume) for 15 minutes at 
room temperature. After washing, streptavidin H R P (1:10000) was added 
/ 
and incubated for another 15 minutes. After washing, O P D substrate was 
then added and absorbance was measured at 492 nm. Results are mean 士 
SD of 3 determinations. 
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3.1.3 Binding of cy-3 to the cytochrome c dotted on PVDF membrane 
With the monoclonal aptamer cy-3, Western blot analysis with cytochrome c of 
various concentrations was performed again. Cy-3 was amplified from purified 
plasmid by PGR with excess biotinylated 5' forward primer. PGR product was used 
to label the cytochrome c dotted on PVDF membrane. 
Results below show that the cy-3 could label cytochrome c in a dose dependent 
manner (Fig. 3.5). In this Western blot, 0.25 |xg of cytochrome c seemed to be the 
detection limit. 
Fig. 3.5. Binding of cy-3 with cytochrome c by dot plot. 
Cytochrome c of various amounts was dotted on a P V D F membrane with 
1% (w/v) B S A as a non-specific binding blocker. The membrane was then 
‘ labeled with cy-3 (1:400) for 1 hour and then incubated with streptavidin 
conjugated H R P (1:10000) for another hour in binding buffer with 1% 




3.1.4 Test the binding of cy-3 with cytochrome c by ELISA 
In this assay, we were trying to study the binding of cy-3 to cytochrome c by 
ELISA. Cytochrome c was first coated on a 96 wells plate in 2-fold dilutions and 
non-specific blocking was done by 1% (w/v) BSA. Cy-3 (1 nmol/ml, 100 [i\) in 1% 
(w/v) B S A binding buffer was added to each well after heating at 95 for 3 minutes. 
After incubating for 1 hour, the wells were washed with binding buffer for 5 times. 
One hundred |il streptavidin H R P (1:10000) in 1% (w/v) B S A binding buffer was 
added to each well and incubated for another hour. O P D as the substrate of H R P was 
added to each well and incubated for 30 minutes at 37 °C. Yellowish colour product 
was then measured at O D 492 nm. 
The results are shown in Fig. 3.6. From the graph, cy-3 was found to bind 
cytochrome c in a dose-dependent manner. The amount of yellowish product 
produced increased with the amount of cytochrome c until it leveled off when the 
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Fig. 3.6. Binding of cy-3 with cytochrome c in ELISA assay. 
Cytochrome c was coated on 96 well-plate in 2-fold dilutions started at 
concentration 8 |ig /100 \i\ per well. After labeling with 100 pmol cy-3 and 
streptavidin, O P D substrate was added. O D at 490 n m was then measured 
which is directly proportional to the amount of yellowish product 




3.1.5 Competitive binding between monoclonal aptamer cy-3 and 
anti-cytochrome c antibody 
To test whether cy-3 and the anti-cytochrome c antibody bind to the same 
epitope of cytochrome c, a competitive ELISA was performed. In this assay, 
cytochrome c was first blocked with a decreasing amount of monoclonal aptamer 
cy-3. After washing, the blocked cytochrome c was labeled with anti-cytochrome c 
and anti-mouse H R P conjugated antibody. From the results, it was found that no 
inhibition was observed suggesting that monoclonal aptamer cy-3 could not block 
the binding between anti-cytochrome c antibody and cytochrome c. This may due to 
the fact that monoclonal aptamer and the antibody recognized different epitopes of 
cytochrome c. 
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Fig. 3.7. Competitive ELISA of cytochrome c between aptamer cy-3 and 
anti-cytochrome c antibody 
Cytochrome c was coated on a 96 wells plate at a concentration of 1 ^ ig/ 
100 i^l per well. Different amounts of gel-purified cy-3 were added and 
then incubated for 1 hour. After washing, cytochrome c were quantified 
by anti-cytochrome c antibody (1:10000) and anti-mouse antibody with 
H R P (1:10000) in 0.1% (w/v) B S A binding buffer. After washing, O P D 
substrate was added. O D at 490 n m was then measured. Results are mean 
土 SD of 3 determinations. 
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3.1.6 Western blotting of pure cytochrome c by cy-3 
During the course of studying of apoptotic proteins, we found that 
commercially available cytochrome c contains a number of dimers, trimers or 
polymers of cytochrome c after SDS-PAGE. To examine whether cy-3 reacts with 
the polymers, cy-3 was tested for the binding of cytochrome c after SDS-PAGE. 
As shown in Fig. 3.8, cy-3 could label the cytochrome c only at the position of 
15 kDa while anti-cytochrome c antibody labeled some high molecular weight 
proteins. The high molecular weight proteins may be the dimers, trimers or tetramers 
of cytochrome c. However, the sensitivity of the cy-3 against cytochrome c was 
lowered than that of antibody as the detection limit of cy-3 was found to be 0.5 |ig at 
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Fig. 3.8. Binding of cy-3 with cytochrome c after SDS-PAGE. 
Pure cytochrome c was loaded to the lanes of a 12% SDS-PAGE from 
right to left with the amount as indicated. After electrophoresis, the 
proteins were then transferred to P V D F membranes and non-specific 
blocking was made by 1% (w/v) BSA. The membranes were then labeled 
with (a) anti-cytochrome c antibody (1:2000) or (b) cy-3 (1:400) in 1% 
* 
(w/v) B S A TBS-T or binding buffer for 1 hour respectively and then 
labeled with (a) anti-mouse H R P conjugated antibody (1:1000) or (b) 
streptavidin H R P (1:10000) respectively for another hour. ECL assay was 
done and signal was generated on an X-ray film. 
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3.1.7 Western blotting of pure cytochrome c from different species 
The cytochrome c as the target of the selection in the pervious chapters was 
extracted from horse. In this chapter, cytochrome c from different species (chicken, 
horse, rat，tuna and yeast) were separated by 15% SDS-PAGE and transferred to 
P V D F membranes. They were then labeled with anti-cytochrome c antibody and 
monoclonal aptamer cy-3. 
From the results (Fig. 3.9)，it was found that cy-3 could label cytochrome c 
from all the species tested, but antibody could not label the cytochrome c from yeast. 
This suggests that cy-3 bind to a universal common site on cytochrome c. Moreover, 
proteins bands with a higher or lower molecular size of 15 kDa were observed in the 
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Fig. 3.9. Different species of cytochrome c labeled with anti-cytochrome 
c antibody and monoclonal cy-3. 
Cytochrome c of chicken, horse, rat, tuna and yeast (1 and 2 jig) were 
separated by 15% SDS-PAGE. The separated proteins were then 
transferred to P V D F membranes and non-specific binding was blocking 
by 1 % (w/v) BSA. The membranes were then labeled with (a) 
anti-cytochrome c antibody (1:2000) or (b) cy-3 P C R product (1:400) in 
lo/o (w/v) B S A TBS-T or binding buffer respectively for 1 hour. 
Subsequently, membranes were labeled with (a) anti-mouse H R P 
conjugated antibody (1:1000) or (b) streptavidin H R P (1:10000) 
respectively for another hour. After washing, E C L assay was done and 
signal was exposed on an X-ray film. 
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3.1.8 Cell lysate SDS-PAGE labeled with cy-3 
After testing the cy-3 for pure cytochrome c, we then examined whether cy-3 
could bind to the cytochrome c in a mixture of cell lysate by Western blotting. By 
using lysis buffer with digitonin (400 |Lig/ 4 x 10^ cells), total cell proteins including 
those in mitochondria were extracted. The total cell lysate was then separated by 
SDS-PAGE and transferred to a P V D F membrane. After blocking with 1% (w/v) 
BSA，the membrane was labeled with cy-3 or anti-cytochrome c antibody. 
The results shown in Fig. 3.10 indicate that cy-3 labeled the cytochrome c as 
well as other cytosolic proteins. In the case with antibody, cytosolic proteins other 
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Fig. 3.10. Binding of cy-3 and anti-cytochrome c antibody with total cell 
lysate. _ 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 jug/ 4 x 10^ cells). Cellular proteins were then 
separated by 12% SDS-PAGE. Started from the right, 20 of the total 
cell lysate was loaded to the wells with a 2-fold dilutions. The separated 
proteins were then transferred to P V D F membranes and non-specific 
binding was blocked by 1% (w/v) BSA. The membranes were then labeled 
‘ with (a) anti-cytochrome c antibody (1:2000) or (b) cy-3 P G R product 
(1:400) in 1% B S A (w/v) TBS-T or binding buffer respectively for 1 hour. 
Subsequently, membranes were labeled with (a) anti-mouse H R P 
conjugated antibody (1:1000) or (b) streptavidin H R P (1:10000) 
respectively for another hour. After washing, ECL assay was done and 
signal was exposed on an X-ray film. 
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3.1.9 Cell lysate labeled with cy-1 to cy-9 after SDS-PAGE 
From the result of Fig. 3.10, it was found that cy-3 labeled other cytosolic 
proteins. This may be due to the fact that the sequence of the cy-3 produced a unique 
3 dimensional structure that bound the cytosolic proteins with a common core 
structure. Therefore, cy-3 may not be a specific clone of aptamer just for cytochrome 
c. 
In this connection, other 8 clones, cy-1, cy-2, cy-4 to cy-9, were amplified from 
plasmid by using PCR and their ability to bind to cytochrome c from cell lysate was 
investigated. 
Results in Fig. 3.11 show that all the monoclonal aptamers bound cytochrome c 
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Fig. 3.11. Binding of cy-1, cy-2 and cy-4 to cy-9 with cell lysate after 
SDS-PAGE. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 \ig/ 4 x 10^ cells). Cellular proteins were then 
separated by 12% SDS-PAGE and transferred to P V D F membranes. 
Non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then labeled with cy-1, cy-2 and cy-4 to cy-9 P C R 
products (1:400) as indicated in 1% (w/v) B S A binding buffer for 1 hour. 
Subsequently, membranes were labeled with streptavidin H R P (1:10000) 
for another hour. After washing, ECL assay was done and signal was 
exposed on an X-ray film. 
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3.2 Selection of cytochrome c-specific aptamer with 
counter selection against cytosolic protein 
The results above (Fig. 3.10 and Fig. 3.11) show that the aptamers selected 
bound to cytochrome c and other cytosolic proteins. This may be due to a possibility 
that the aptamers selected (cy-1 to cy-9) might fold into 3-dimensional structures that 
could recognize cytosolic proteins. 
To eliminate these unwanted bindings, the pool of oligonucleotides was first 
counter selected against cytosolic proteins before the selection with cytochrome c. 
Those aptamers bound to cytosolic proteins would be discarded. 
To increase our success rate, we employed three different methods for the 
counter selection against the cytosolic proteins. 
3.2.1 Selection of aptamer against cytochrome c with counter selection 
against cytosolic cell lysate 
In the first method, the cytosolic cell lysate was extracted from growing L929 
with lysis buffer containing a low dose of digitonin (12.5 |Lig/ 4 x 10^ cells). By using 
this dosage of digitonin, only the plasma membrane was permeabilized but not the 
mitochondrial membrane. Thus, proteins in mitochondria including cytochrome c 
will not be extracted. After extraction, cytochrome c free cytosolic proteins were 
dotted on a P V D F membrane for counter selection. 
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In this preparation, 100 pmol of the oligonucleotides in the library were used. It 
first performed a cycle of counter selection against B S A on P V D F membranes. 
Those oligonucleotides that did not interact with B S A membrane were collected. In 
the second round selection, oligonucleotides from the first round reaction were 
incubated with cytochrome c on P V D F membrane. After washing and elution, 
oligonucleotides reacted with cytochrome c were amplified by PCR. The products 
were subject to another round of counter selection against cytosolic cell lysate 
(which is extracted with lysis buffer containing a low dose of digitonin as mentioned 
before) saturated on P V D F membrane for about 6 hours followed by a selection 
against cytochrome c coated on P V D F membrane. 
The aptamers selected were then amplified again and biotinylated. Western blot 
was used to test the binding of the aptamer to the total cell lysate and the results are 
shown in Fig. 3.12. 
From the results，it can be found that the aptamer selected could bind both the 
cytochrome c and cytosolic proteins even after counter selection with the 
cytochrome c free cytosolic proteins. Also, the binding pattern was similar to those 
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Fig. 3.12. Effect of the counter-selection with cytosolic proteins on the 
selection of cytochrome c specific aptamer. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 \igl 4 x 10^ cells). Cellular proteins were separated 
by 15% SDS-PAGE and transferred to P V D F membranes. Non-specific 
binding was blocked by using 1% (w/v) BSA. The membranes was then 
labeled with the aptamer (selected after counter selection with cytochrome 
c free cytosolic proteins) for 1 hour in 1% (w/v) B S A binding buffer and 
then labeled with streptavidin H R P (1:10000) for another hour. ECL assay 





3.2.2 Selection of aptamer against cytochrome c by fixed cell followed by 
cytochrome c elution 
In the second counter selection, process was started by using 100 pmol 
oligonucleotides from the pool with 40 random nucleotides. To eliminate those 
oligonucleotides that could bind the blocking agent BSA, the pool was first counter 
selected against B S A for 1 hour. The oligonucleotides remained in the binding buffer 
was transferred and incubated with fixed cells for 2 hours. After washing with 
binding buffer, cytochrome c specific aptamers were then eluted by 400 |il 100 ng/ml 
cytochrome c in binding buffer with decreasing time intervals from 1 hour, 45 
minutes，30 minutes or 15 minutes in the final round of selection for the high affinity 
aptamers. 
Those aptamers selected were amplified by PCR with biotinylated 5' forward 
primer. The biotinylated aptamers were then used to label the cell lysate after 
SDS-PAGE (Fig. 3.13). Unfortunately, aptamers were found to bind to cytochrome c 
and cytosolic proteins. Also, it seems likely that the affinity between the aptamers 
and cytochrome c was not strong. Yet, the binding pattern was different from Fig. 
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Fig. 3.13. Western analysis of the binding of cell lysate to aptamers 
selected by fixed cell followed by cytochrome c elution. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 |Lig/ 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to a P V D F membrane. 
Non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then labeled in 1% (w/v) B S A binding buffer for 1 hour 
with the aptamers selected by fixed cell and eluted by cytochrome c. 
Subsequently, membranes were labeled with streptavidin H R P (1:10000) 
for another hour. After washing, ECL assay was done and signal was 




3.2.3 Selection of aptamer from cytochrome c band 
In the Western blot analysis, the aptamer selected was found to bind to both the 
cytosolic protein and cytochrome c on PVDF membrane (Fig. 3.12). To have 
cytochrome c specific aptamer, aptamers on the band of cytochrome c should be 
highly specific to the cytochrome c. With this rationale in our mind, we cut the band 
of cytochrome c out of the PVDF membrane labeled with the aptamers selected with 
counter selection against cytosolic cell lysate (section 3.2.1) and eluted the aptamers 
by elution buffer. After amplification by PCR and biotinylation, the aptamer eluted 
were tested for protein binding again with Western blot analysis (Fig. 3.14). 
From the results (Fig. 3.14)，it can be seen that the aptamer eluted from 
cytochrome c band could bind to cytochrome c and cytosolic proteins. Interestingly, 
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Fig. 3.14. Western analysis of the binding of aptamers from the 
cytochrome c band to cytosolic proteins. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 \igl 4 x 10^ 'cells). Cellular proteins were separated 
by 15% SDS-PAGE and transferred to a P V D F membrane. Non-specific 
binding was blocked by using 1% (w/v) BSA. The membranes was then 
labeled with the aptamer eluted from the band of cytochrome c for 1 hour 
in 1% (w/v) B S A binding buffer and then labeled with streptavidin H R P 
(1:10000) for another hour. The ECL assay was done and signal was 




3.3 Primers Testing 
3.3.1 Cell lysate labeled with primers after SDS-PAGE 
All the clones (cy-1 to cy-9) tested were found to label cytosolic proteins with a 
similar pattern (Fig. 3.11). And even the aptamers eluted from the band of 
cytochrome c could bind to other cytosolic protein in a similar way (Fig. 3.12 and 
3.14). This may be due to the presence of a common item in the labeling solution 
that leads to the non-specific binding of cytosolic protein. In our study, all the tested 
clones were developed by P C R reactions in which excess amount of biotinylated 
forward 5' primers were added. This is necessary because without the biotinylated 
forward 5' primer, no signal will be given since it contains biotin for the recognition 
of streptavidin H R P and it should be in excess to make sure that aptamers so 
produced were the single sense strand. In light of this, biotinylated forward 5' 
primers were used to examine whether the forward 5，primers label the cell lysate on 
membrane. 
Results from Fig. 3.15 show that Biotinylated forward 5' primers could label 
cytosolic proteins but not cytochrome c. Also, the binding pattern was different from 
the previous ones. These observations suggest that the non-specific binding with the 
cytosolic proteins other than cytochrome c in the results of the previous chapters 
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Fig. 3.15. Western analysis of the forward 5' primers with cell lysate. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 \igl 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to PVDF membranes. 
Non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then labeled with 100 pmol biotinylated 5' primer (a) or 
aptamer selected with counter selection against cytochrome c free cell 
lysate (b) in 1% (w/v) B S A binding-buffer for 1 hour and then labeled with 
streptavidin H R P (1:10000) for another hour. ECL assay was done and 
signal was exposed on an X-ray film. 
3.3.2 Cell lysate labeled with cy-3 without primer 
Since the biotinylated 5' forward primer was found to bind cytosolic proteins 
, (Fig. 3.15), they were eliminated from the aptamers before labeling with the total cell 
> 
lysate. The P C R products of cy-3 were purified by using 12% polyacrylamide with 7 
M urea denaturing gel. The cy-3 were then eluted from the gel and used to label cell 
lysate separated by SDS-PAGE and the Western analysis was shown in Fig. 3.16. 
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Fig. 3.16. Western analysis of purified cy-3 without the contamination of 
forward 5' primers with cell lysate. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 [ig/ 4 x 10^ cells). The cellular proteins were then 
separated by 15% SDS-PAGE and transferred to a P V D F membrane and 
non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then labeled with purified cy-3 (without biotinylated 
5'primer) in 1% (w/v) B S A binding buffer for 1 hour and then labeled with 
streptavidin H R P (1:10000) for another hour. E C L assay was done and 
signal was exposed on an X-ray film. 
From the results (Fig. 3.16), it can be seen that cy-3 after the removal of the 
excess 5' primers still bound to other cytosolic proteins non-specifically in addition 




3.3.3 Test the effect of sense oligonucleotide 
Next, we tried to examine whether the non-sense oligonucleotides produced 
during P C R contributed to the non-specific binding in the Western blot analysis. 
After the P C R and purification by denaturing gel, the biotinylated aptamers were 
captured by using streptavidin paramagnetic beads after heated at 95 Under this 
condition, only the sense strands were captured and they were then eluted and used 
for labeling. 
From the results, the biotinylated sense aptamer strands showed non-specific 









Fig. 3.17. Western analysis of purified cy-3 without the contamination of 
non-sense oligonucleotides with cell lysate. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 \ig/ 4 x 10^ cells). The cellular proteins were then 
separated by 15% SDS-PAGE and transferred to a P V D F membrane and 
non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then labeled with purified cy-3 (without biotinylated 
5'primer and the antisense oligonucleotide) in 1% (w/v) B S A binding 
buffer for 1 hour and then labeled with streptavidin H R P (1:10000) for 




3.3.4 Sequence of monoclonal aptamer 
With the results from Fig. 3.15 and 3.16, it is possible that the primer sequence 
at the 5' end of the cy-3 aptamers attached to the cytosolic proteins. To investigate 
this possibility, we tried to remove the primer sequences from aptamers cy-1 to cy-3. 
Yet, after the elimination of the primer sequence from the aptamers, the aptamers 
could not be produced by PCR anymore. The aptamers could only be synthesized by 
oligonucleotide synthesizer according to the sequence. Thus, aptamers cy-1 to cy-3 
were sequenced by an automated D N A sequencer. Their flanked primer sequences 
and core sequences are shown in Fig. 3.18a. The predicted secondary structures of 
the aptamers with or without flanked primers are also illustrated in Fig. 3.18. As 






Conserved 5' region for primer binding 
Cy-1: GAACTAGAGTTGCATCTCTCGCCGGCTTACGGCTCGAACC 
Cy-2: G T A G G G T G G T G A G C T C G G G G T T A T C T C C C T A G G G C C A T T A C 
Cy-3: CCGTGTCTGGGGCCGACCGGCGCATTGGGTACGTTGTTGC 
-CGTAG/L47TCCTGCAGCC 3’ 
Conserved 3，region for primer binding 
(b) Cy-1 Cy-2 Cy-3 
入 ^'CT \ rf 
背 \ / 
(c) Cy-1 Cy-2 Cy-3 
5’ 3' 
^ / / 
Fig. 3.18. The sequences and the secondary structures of aptamer cy-1 to 
cy-3. 
(a) The flanked primer sequence and the core sequence. Bold letters show 
the cutting site for Hind III enzyme. Bold italic letters show the cutting site 
for Eco RI enzyme. 
With the nucleotide sequences, the predicted secondary structures of the 
aptamer cy-1 to cy-3 with (b) or without (c) flanked primers were predicted 




3.3.5 Cell lysate labeled with aptamers without primer ends 
The core sequence of aptamer cy-3 was synthesized according to the result of 
sequencing with a biotin conjugated at 5' end. The synthesized aptamer was called 
BS-cy3. BS-cy3 was then allowed to react with cell lysate and results are shown in 
Fig. 3.19. Unfortunately, the core sequence of the aptamer cy-3 which did not have 
the primer sequences also labeled cytosolic proteins and cytochrome c. However, the 
binding pattern was unique and more cytosolic proteins were labeled. 
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Fig. 3.19. Western analysis ofBS-cy3 with cell lysate after SDS-PAGE. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 ^g/ 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to a P V D F membrane. 
Non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then labeled with 100 pmol BS-cy3 (the core sequence of 
‘ the aptamer cy-3, without the 5' forward and 3, reverse primers sequences) 
in 1% (w/v) B S A binding buffer for 1 hour and then labeled with 
streptavidin H R P (1:10000) for another hour. ECL assay was done and 
signal was exposed on an X-ray film. 
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3.3.6 Test of the aptamers after mutations 
In this part, we introduced point mutations in the monoclonal aptamer cy-3 
according to the result of sequencing. By the prediction of the software, the 
secondary structures of the mutants were different from that of cy-3. Cy-3 and its 
mutants including the flanked ends were synthesized with biotin conjugated at 5’ end 
and tested for the binding to cytochrome c by Western blotting. 
With the mutation, the secondary structures of the mutants were found to be 
different from the original aptamer (Fig. 3.20) After testing for labeling, our results 
showed that cy-3-3 could bind to cytochrome c with a higher affinity (in terms of 
intensity) after mutation while cy-3-2 showed a lower affinity to the cytochrome c 
(Fig. 3.21). Cy-3-2 also showed a non-specific binding as a small band at the size of 
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Fig. 3.20. The sequences and the secondary structures of aptamers after 
mutation. 
(a): The sequences of the original aptamers cy-3 and its mutants 
‘ (cy-3-2 and cy-3-3). The nucleotides underlined were the points of 
mutation, (b): With the prediction by using Vienna R N A Secondary 
Structure Prediction and Comparison Programme, the secondary structures 
of the aptamers before and after mutation were shown. 
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Fig. 3.21. Labeling of cell lysate with mutants of cy-3. 
L929 were seeded in a 6 wells plate (1 x 10^ cells per well) overnight. The 
cells were then incubated with medium alone (C) or TNF-a (50 ng/ml) (T) 
for 6 hours at 37 5 % CO2. After treatment, the cells were washed with 
PBS and total cell lysate were extracted with lysis buffer containing a high 
dose of digitonin (400 fig/ 4 x 10^ cells). Cellular proteins and 1 ^g 
cytochrome c (1 |ag) were then separated by 15% SDS-PAGE. The 
separated proteins were then transferred to P V D F membranes. 
Non-specific binding was blocked by 1% (w/v) BSA. The membranes 
were then labeled with 100 pmol (a) cy-3, (b) cy-3-2 or (c) cy-3-3 in 1% 
(w/v) B S A binding buffer for 1 hour and then labeled with streptavidin 
H R P (1:10000) for another hour. ECL assay was done and signal was 




3.3.7 Test for other biotinylated primer 
In the literature, single protein band was developed with a monoclonal aptamer 
against cellular proteins ERK2 in the Western blot analysis (Bianchini et al., 2001). 
This suggests that their primer set might be a good start for aptamer development. 
With this thought in our mind, same primers with biotin conjugated were synthesized 
and their binding to cell lysate was examined. The sequences of the primers used in 
this experiment were: 
ERK2-F0R: T C C A T T C A C A G A C C T T T T G A G C 
ERK2-REV: G A C A C A C G C C T C T A T C A T A T C A 
Labeling the cell lysate with this pair of primers in the condition we used was 
performed, results were different from the work done by Bianchini et al. (2001). Our 
results in Fig. 3.22 show that the primers also bound the cytosolic proteins. 
Interestingly, the binding pattern of ERK2-F0R and ERK2-REV was more or less 
the same (Fig. 3.22). However, with the labeling condition used by Bianchini et al., 
that is blocked the P V D F membrane 职d labeling with 5 % (w/v) milk, his primer 
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Fig. 3.22. Western analysis of the ERK2-Forward and ERK2-Reverse 
primers with cell lysate. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 |ag/ 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to P V D F membranes. 
Non-specific binding was blocked by using (a) 1% (w/v) B S A or (b) 5 % 
(w/v) milk. The membranes were then labeled with the forward or reverse 
primers (100 pmol) in (a) 1% (w/v) B S A or (b) 5 % (w/v) milk in binding 
buffer for 1 hour and then labeled with streptavidin H R P (1:10000) for 
another hour. E C L assay was done and signal was exposed on X-ray films. 
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3.4 Elimination of non-specific binding 
3.4.1 Different types of cell lysate 
To test if other cell lysate can be labeled non-specifically with the biotinylated 
primers, cell lysates of different cell lines including L929, HL-60 and HepG2 cells 
were collected. After Western blotting, the cell lysates were labeled with biotinylated 
primer (the pair used in our own selection) (Fig. 3.23). 
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Fig. 3.23. Western analysis primer with cytosolic proteins from different 
cell lines. 
Total cell lysate of L929 (L)，HepG2 (H，）and H L 60 (60) were extracted 
with lysis buffer containing a high dose of digitonin (400 )j.g/ 4 x 10^ cells). 
Cellular proteins were separated by 15% SDS-PAGE and transferred to 
P V D F membranes. One of the membranes was stained by coomassie blue 
(a) and the other one was incubated with 1% (w/v) B S A for non-specific 
blocking (b). The membranes blocked were then labeled with biotinylated 
5' forward primer in 1% (w/v) B S A binding buffer for 1 hour and then 
labeled with streptavidin H R P (1:10000) for another hour. ECL assay was 
done and signal was exposed on an X-ray film. 
Results in Fig. 3.23 show that the biotinylated primer could label the total cell 
lysate from different cell types non-specifically in a similar way. 
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3.4.2 Heating effect on the non-specific binding 
Binding of aptamer to its target is believed to be mediated by the 
three-dimensional structure of the aptamer which is sequence specific. To test if the 
non-specific binding was a result of the recognition of the cytosolic proteins with the 
sequence specific structure of the oligonucleotide, the primers were removed by 
heating at 95 for 3 minutes. 
In this experiment, the Western blotted membrane was first labeled with 
forward primers, and then streptavidin HRP. The membrane was washed in binding 
buffer for three times 15 minutes each, once at room temperature, once at 95 °C and 
then the last one at room temperature again. After washing, streptavidin H R P was 
then loaded to the membrane again. 
Results of the assay after heating treatment are illustrated in Fig. 3.24. It can be 
seen from the results that the binding between aptamers and cytosolic proteins could 
not be dissociated by heating. This suggests that the non-specific binding may not be 
mediated by sequence-dependent secondary structures of the oligonucleotides. It 
may be a result of charge-charge interaction between the D N A and protein or due to 
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Fig. 3.24. Heating effect on the non-specific binding of cellular proteins to 
biotinylated 5' forward primers. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 ng/ 4 x 10^ cells). Cellular proteins were separated 
by 15% SDS-PAGE and transferred to P V D F membranes. Non-specific 
binding was blocked by using 1 % (w/v) B S A in binding buffers. The 
membranes was then labeled with 100 pmol biotinylated 5' forward 
primers or 3' reverse primers as indicated in 1% (w/v) B S A binding buffers 
for 1 hour and then labeled with streptavidin H R P (1:10000) for another 
hour. After that the membrane was washed three times at room temperature, 
..95。C and then room temperature again. Streptavidin H R P (1:10000) was 





3.4.3 Using milk as a blocking agent 
3.4.3.1 Milk blocked membrane 
For Western blotting, B S A 1% (w/v) and milk 5 % (w/v) are commonly used as 
blocking agents. In this part of the experiment, 5% (w/v) milk was used instead of 
1% (w/v) B S A to block the P V D F membrane after the proteins were transferred to 
the membrane. Western blot analysis was performed as before. 
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Fig. 3.25. Effect of milk as a blocking agent. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 |ig/ 4 x 10^ -cells). Cellular proteins were separated 
by 15% SDS-PAGE and transferred to P V D F membranes. Non-specific 
binding was blocked by using (a) 1% or (b) 5 % (w/v) milk. The 
membranes was then labeled with 100 pmol biotinylated 5' forward primer 
in (a) 1 % or (b) 5 % (w/v) milk binding buffer for 1 hour and then labeled 
with streptavidin H R P (1:10000) for another hour. ECL assay was done 
and signal was exposed on an X-ray film. 
• 
Results from Fig. 3.25 indicate that the binding of oligonucleotides to cellular 




3.4.3.2 Milk prevented the binding of aptamer to cytochrome c 
From the results above, it was found that nothing can be probed in the presence 
of 5% (w/v) milk. There are two possible explanations for this observation. First, 
milk may dissociate the non-specific binding between proteins and oligonucleotides. 
Alternatively, it can prevent the binding between the proteins and oligonucleotides. 
To explore these possibilities, Western blot analysis with aptamer was 
performed as described before by using 1% (w/v) B S A as blocking agent. After the 
ECL assay, the membrane was then incubated with 5% (w/v) milk at 4 °C overnight. 
On another day, anti-streptavidin H R P was loaded again. For another membrane, the 
cell lysate was probed with biotinylated 5' forward primer together with 5% (w/v) 
milk and then with streptavidin HRP. 
Results in Fig. 3.26 indicate that the binding between proteins and the 
oligonucleotides could not be dissociated after incubation with 5% (w/v) milk 
overnight. However, the 5 % milk could prevent the binding between the proteins and 
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(a) (b) (c) 
Fig. 3.26. Effect of milk as a blocking agent on the aptamer-protein 
binding. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (25 \igl 4 x 10^ cells). Cellular proteins were dotted on 
P V D F membranes. Non-specific binding was blocked by 1% (w/v) BSA. 
(a) The membranes were then labeled with biotinylated 5' forward primer 
in 1% (w/v) B S A in binding buffer for 1 hour and then labeled with 
streptavidin H R P (1:10000) for another hour, (b) The membrane from (a) 
was incubated in 5 % (w/v) milk binding buffer overnight at 4 and then 
labeled with streptavidin H R P (1:10000) for another hour, (c) Another 
membrane labeled with biotinylated 5' forward primer in 5 % milk in 
binding buffer for 1 hour and then labeled with streptavidin H R P (1:10000) 
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3.4.3.3 Cell lysate labeled with cy-3 after SDS-PAGE by using milk as 
blocking agent 
As 5 % milk was found to block the binding between cellular proteins and 5' 
primers effectively, cy-3 was tried to label with cell lysate after SDS-PAGE by using 
5 % milk as a blocking agent. 
< 
Fig. 3.27. Binding of cy-3 with cell lysate after SDS-PAGE by using 5 % 
milk as a blocking agent. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (25 |ig/ 4 x 10^ cells). Cellular proteins were dotted on 
P V D F membranes. Non-specific binding was blocked by using 5 % (w/v) 
milk. The membranes were then labeled with 100 pmol gel purified cy-3 in 
5 % (w/v) milk in binding buffer for 1 hour and then labeled with 
streptavidin H R P (1:10000) for another hour. ECL assay was done and 
signal was exposed on an X-ray film. 
Results in Fig. 3.27 showed that milk blocked all the binding of cy-3 with 
‘ cytosolic proteins suggesting that cy-3 could not labeled cytochrome c in the 
presence of 5 % milk. It may be due to the fact that the selection of cy-3 was not 
performed in a condition with milk, so it could not recognize cytochrome c in this 
new condition. 
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3.4.3.4 Aptamer selection against cytochrome c in the presence of milk 
In order to select and aptamer for cytochrome c with the use of milk as a 
blocking agent, the selection was started again by using 100 pmol oligonucleotides 
with 40 random nucleotides. In this new selection process, the pool was first counter 
selected with a PVDF membrane blocked by 5% milk to eliminate those 
oligonucleotides that could bind to the milk components. The oligonucleotides 
remained were transferred to and incubated with a PVDF membrane which was 
saturated with 20 )ig/ml denatured cytochrome c and blocked with 5% milk. After 
washing with binding buffer, the bound aptamers were eluted by using 40 |ig/ml 
native cytochrome c. After PCR amplification, the PCR products were separated by 
12% polyacrylamide 7 M urea denaturing gel (data not shown). Oligonucleotides 
with suitable size were found suggesting that by 5 % (w/v) milk blocked cytochrome 
c on P V D F membrane could select aptamer from the pool. 
In Western blot analysis, the proteins were denatured that their conformations 
may be different from that of native foms and they may be recognized by different 
aptamers. In this set of selection, the cytochrome c on the P V D F membrane was 
denatured by mixing with 2X SDS-loading buffers which contained SDS and boiling 
for 5 minutes before dotted on membrane. Using denatured cytochrome c as a target 
of aptamer selection, we should be able to select those oligonucleotides that could 
bind to the denatured cytochrome c in the Western blotting. Moreover, during the 
selection, the aptamers bound to the denatured cytochrome c were eluted by native 
cytochrome c. These eluted aptamers were collected and should be able to bind to 
both native and denatured cytochrome c. 
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After 5 rounds of selection, the aptamers selected were amplified and 
biotinylated. The biotinylated aptamers were used to label the cell lysate after 
SDS-PAGE by using 5 % milk as a blocking agent. 
From the results of Fig. 3.28, it was found that the aptamers selected bound 
cytosolic proteins but not cytochrome c if 1% B S A was used as blocking agent while 
they did not bind to cytochrome c and other cytosolic protein if 5 % milk was used. 
(a) (b) 
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Fig. 3.28. Binding of the aptamer selected in the presence of milk with cell 
lysate after SDS-PAGE. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (25 jag/ 4 x 10^ cells). Cellular proteins were dotted on 
P V D F membranes. Non-specific binding was blocked by using (a) 1% 
B S A (w/v) or (b) 5 % (w/v) milk. The membranes was then labeled with 
100 pmol gel purified aptamer selected in the presence of milk in (a) 1% 
(w/v) B S A or (b) 5 % (w/v) milk in binding buffer for 1 hour and then 
* 
labeled with streptavidin H R P (1:10000) for another hour. ECL assay was 
done and signal was exposed on an X-ray film. 
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3.4.4 Using DNA as a Blocking agent 
3.4.4.1 DNA blocked the non-specific binding 
From the results in Fig. 3.14 and Fig. 3.24, the non-specific binding of the 
oligonucleotides to the cytosolic proteins seems to be sequence-independent. With 
the use of different oligonucleotides of different sequences, the outcome in terms of 
labeling pattern with the total cell lysate was similar. This may be due to the 
presence of proteins on the membrane which could bind D N A molecules. 
To test this possibility, we tried to use calf thymus D N A to block the 
non-specific binding before the addition of biotinylated forward primer. As shown in 
Fig. 3.29，100 \ig D N A could partially block the binding of the primers to the 
cytosolic proteins arid 150 could totally remove the binding. 
I 
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Fig. 3.29. The use of D N A as blockers to eliminate non-specific binding 
from biotinylated 5，forward primer. 
L929 total cell lysate was extracted with lysis buffer containing a high 
dose of digitonin (400 |ig/ 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to P V D F membranes. 
Non-specific binding was blocked by using 1% (w/v) BSA. The 
membranes were then incubated without (a) or with (b) 100 |ig or with 150 
|Lig (c) sonicated calf thymus D N A in 1% (w/v) B S A binding buffer for 1 
hour. The membranes were then labeled with biotinylated 5' forward 
primers also in 1% (w/v) B S A binding buffer for 1 hour and then labeled 
with streptavidin H R P (1:10000) for another hour. E C L assay was done 
and signal was exposed on X-ray films. 
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3.4.4.2 Cell lysate labeled with cy-3 after SDS-PAGE by using DNA as 
blocking agent 
From the results above, D N A could block all the non-specific binding. 
Next, we tried to use calf thymus D N A as a blocking agent in the Western 
analysis with different monoclonal aptamers (cy-1 to cy-4) against the total cell 
lysates. Results from Fig. 3.30 indicate that aptamer cy-1 to cy-4 could not label 
cytochrome c and cytosolic proteins after blocking with DNA. 
IP 4 _ 
Cy-1 Cy-2 Cy-3 Cy-4 
Fig. 3.30. The use of D N A as blockers to eliminate non-specific binding 
from cy-1 to cy-4. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 {ig/ 4 x 10^  cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to P V D F membranes and 
non-specific binding was blocked by using 1% (w/v) B S A in binding 
buffers. The membranes were then blocked with 75 |ag/ml calf D N A in 
‘ binding buffer and then labeled with cy-1 to cy-4 as indicated in 1% (w/v) 
B S A binding buffers for 1 hour and then labeled with streptavidin H R P 
(1:10000) for another hour. ECL assay was done and signal was exposed 
on X-ray films. 
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3.4.4.3 Selection against cytochrome c blocked by DNA 
From Fig. 3.30, aptamer cy-1 to cy-4 could not label cytochrome c and 
cytosolic proteins after blocking with DNA. This may be due to the fact that the 
presence of D N A on the PVDF membrane interfered the binding between aptamers 
cy-1 to cy-4 to the cytochrome c. 
To improve this situation, aptamers were selected against cytochrome c coated 
on P V D F membrane with D N A as blocking agent. After selection, the aptamers 
obtained were amplified and biotinylated by PCR with excess biotinylated 5' 
forward primer. After P C R amplification, the PCR products were checked by 12% 
polyacrylamide 7 M urea denaturing gel (data not shown). Oligonucleotides with 
suitable size were present showing that aptamers could be selected from the library 
by D N A blocked cytochrome c on the PVDF membrane. The biotinylated P C R 
product were then purified by 12% polyacrylamide 7 M urea denaturing gel. The 
purified aptamers were tested for binding by Western analysis (Fig. 3.31). 
From Fig. 3.31, it was found that the aptamers selected against cytochrome c 
blocked by D N A still could not label cytochrome c and other cytosolic proteins. This 
may due to the fact that the calf D N A used for blocking are with different sequences, 
they may block the binding of cytochrome c and cellular proteins with different 
sequence. Alternatively, calf thymus D N A reacted with the selected aptamer and the 
I 
complexes were washed away during the Western analysis. And thus, the calf thymus 
D N A may interfere the recognition between the aptamers and target. 
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Fig. 3.31. Binding of aptamer selection against cytochrome c blocked by 
D N A with cell lysate after SDS-PAGE. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE and transferred to P V D F membranes and 
non-specific binding was blocked by using 1% (w/v) B S A in binding 
buffers. The membranes were then blocked with 75 |ig/ml calf D N A in 
binding buffer and then labeled with the aptamers selected in 1% (w/v) 
B S A binding buffers for 1 hour and then labeled with streptavidin H R P 
(1:10000) for another hour. ECL assay was done and signal was exposed 
on an X-ray film. 
i 
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3.4.4.4 Labeling of cell lysate treated with DNase, RNase or both after 
SDS-PAGE 
Another possibility of generating non-specific bindings between our aptamers 
and total cell lysate is the presence of D N A and R N A which interact with the 
aptamers. In order to eliminate the possible bindings of aptamers to the cellular D N A 
and R N A in the total cell lysates, the total cell lysate was pre-treated with DNase or 
RNase or both to eliminate all the D N A and R N A that may be present in the system 
which interact with aptamers before dotted on PVDF membrane (Fig. 3.32). 
From the results in Fig. 3.32, it is clear that those treated with DNase or RNase 
still produced signals with the primers as the one observed in control (that was not 
treated with DNase. or RNase). These suggest that the D N A and R N A in the total cell 
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Fig. 3.32. Effect of DNase and RNase on the binding of biotinylated 5' 
forward primer with total cell lysate. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 |ig/ 4 x 10^ cells). The cell lysate were then treated 
with DNase, RNase or both (20 |ag/ ml each at 37 for 1 hour) as 
indicated. The treated or untreated cell lysates were dotted on the P V D F 
membrane. After the proteins were coated on the membrane, non-specific 
binding was blocked by 1 % (w/v) BSA. The membranes was then labeled 
with 100 pmol biotinylated 5' forward primer in 1 % B S A binding buffers 
for 1 hour and then labeled with streptavidin H R P (1:10000) for another 
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3.5 Photo-SELEX 
To increase the binding specificity and affinity, Photo-SELEX was used in this 
set of selection. In the Photo-SELEX process, thymidine in the random region was 
replaced by 5-halo-deoxyiiridine. Oligonucleotides with 5 -halo-deoxyuridine can 
form covalent cross linkages with specific aromatic amino acids such as Tyr or Trp 
of the antigen under U V light. This covalent bonding can enhance the binding 
specificity (Meisenheimer et al., 2000). 
3.5.1 Selection process 
Forty pmol of the pool of photo-oligonucleotides were first incubated with 
cytochrome c (final concentration 1.5 nM) in 800 id binding buffer at room 
temperature for 15 minutes with shaking. After washing, the mixture was then 
irradiated by U V light to form cross linkage. The cross linkage complexes were then 
concentrated by using filter and separated by 12% polyacrylamide 7 M urea 
denaturing gel. The cross linking between the photo oligonucleotide and cytochrome 
c was covalent which could not be broken down by heat or urea in the gel. The 
presence of this complex can be seen as a mobility shift in the electrophoresis gel 
when compared to the one without cross-linkages. 
As a control, the photo-oligonucleotide pool was incubated with cytochrome c 
‘ and followed the same steps of signal development but without U V light irradiation. 
> 
The gel photo (Fig： 3.33) shows that after irradiation of U V light, the photo 
oligonucleotide formed complex with the target proteins and ran slower in the 
denaturing gel. However, for the control, it did not show any delay suggesting that 
no complex was formed when no irradiation of U V light was performed. The band 
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which ran slower was cut out, crashed and incubated with 400 |il proteinase K (400 
|ig/ml) in TE buffer at 37 °C overnight to separate the proteins from the 
oligonucleotides. The oligonucleotides were then extracted and amplified by PCR. 
From the gel photo, there was a band with the same size of the marker. However, 
a smear was observed on the top of this band suggesting a mobility shift of a large 
complex with the aptamer. Moreover, except the high molecular weight of large 
complexes, there were a faster band with the same size as the pool and a smear 
below it. The presence of the faster band may be a result of the pool of 
oligonucleotides which was in excess amount to the target proteins. Some 
oligonucleotides remain freely in the reaction. And the present of a smear which 
have smaller size may due to the present of oligonucloetide fragment which broke 
down from the pool. 
Without U V WithUV 、40 ool 
irradiation irradiation P 
Fig. 3.33. A denaturing gel with urea to show the effect of U V light on the 
binding of photo-oligonucleotides to target proteins. 
The photo oligonucleotides incubated with cytochrome c illuminated with 
‘ (for selection) or without (as control) U V light for 2 minutes. After 
concentration, urea and 6X loading dye were added and the mixture was 
heated at 95 °C for 3 minutes before loading to the gel. N40 pool was run 
simultaneously as the size marker. After separated by 12% polyacrylamide 
7 M urea denaturing gel at lOOV for 45 minutes, D N A was stained by 
ethidium bromide and visiblized by U V light. 
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3.5.2 Cell lysate labeled with photo-aptamer 
The photo-oligonucleotides after 5 rounds of selection were used to probe with 
cytochrome c together with cellular proteins by Western blot analysis. As shown in 
Fig. 3.34a and b, a Western blot with 1% (w/v) BSA, they both showed the binding 
with cytochrome c and cytosolic proteins. And the one with U V irradiation (Fig. 
3.34b) showed more non-specific bands than the one without (Fig. 3.34a). On the 
other hand, it was found that the photo-aptamers could not label cytochrome c and 
cytosolic proteins before and after U V irradiation in the presence of 5% (w/v) milk 
(Fig. 3.34c and d). 
* • 
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Fig. 3.34. A Western blot to show the effect of U V light on the binding of 
photo-oligonucleotides to target protein. 
Total cell lysate of L929 was extracted with lysis buffer containing a high 
dose of digitonin (400 |j,g/ 4 x 10^ cells). Cellular proteins were separated 
by 15% SDS-PAGE and transferred to P V D F membranes. Non-specific 
binding was blocked by using (a, b) 1% (w/v) B S A or (c, d) 5 % (w/v) milk. 
The membranes were then labeled with 100 pmol photo-aptamer in 
binding buffer with blocking agent for 1 hour. For the one with U V 
irradiation (b，d)，it was excited by U V for 2 minutes after washing the 
membrane once with binding buffer. The two membranes were then 
labeled with streptavidin H R P (1:10000) for another hour. E C L assay was 
done and signal was exposed on X-ray films. 
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3.5.3 Testing by immunoprecipitation 
To test the binding of photo-aptamer to cytochrome c, we tried to investigate 
whether the photo-aptamer can absorb cytochrome c or not? To test this, cytochrome 
c was obtained by immunoprecipitation. After amplification and biotinylation, the 
photo-aptamers were conjugated on streptavidin paramagnetic beads. The beads 
were then incubated with native cytochrome c for 15 minutes and illuminated with 
U V light for 2 minutes in a system with a fixed amount of cytochrome c. After 
washing, the beads were then incubated with DNase at 37 °C for half an hour. The 
proteins were then added with equal volume of 2X SDS loading buffer and boiled for 
5 minutes. After that, the proteins were analyzed by using Western blotting with 
anti-cytochrome c antibody. As shown in Fig. 3.35, photo-aptamers could pick up 
cytochrome c. However, the photo-aptamers seemed to pick up more of the high 
molecular weight forms than the 15 kDa of cytochrome c suggesting that the high 
molecular weight cytochrome c was also the target protein of the photo-aptamer with 
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Fig. 3.35. Immunoprecipitation by using photo-aptamer. 
Cytochrome c (1.5 iig) were immunoprecipitated by using photo-aptamers 
conjugated on paramagnetic beads and illuminated with U V for 2 minutes. 
After incubation, the oligonucleotides were digested by DNase (10 mg/ml) 
to release the cytochrome c bound. The proteins were separated by 15% 
SDS-PAGE and transferred to P V D F membranes. Non-specific binding 
was blocked by using 5 % (w/v) milk. The membranes were then labeled 
with anti-cytochrome c antibody in 5 % (w/v) milk binding buffer (1:2000) 
for 1 hour and then labeled with H R P conjugated anti-mouse antibody 
(1:2000) for another hour. E C L assay was done and signal was exposed on 
X-ray films. 
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3.6 Application 
3.6.1 Detection of the cytochrome c in cytosolic proteins after treatment of 
TNF-a 
Although we could not eliminate the non-specific binding between the 
monoclonal aptamer with cellular proteins by different experimental designs, the 
semi-quantitation against cytochrome c after SDS-PAGE can be performed if we 
concentrate on the cytochrome c bands only. To investigate this, we tried to use 
aptamer to probe the cytochrome c released from TNF-a treated L929 cells. 
TNF-a induces apoptosis in L929 cells and this process involves the release of 
cytochrome c from mitochondria. The release of cytochrome c can be detected by 
anti-cytochrome c antibody or aptamer in the cytosol of cells. After treatment of cells 
with TNF-a, the cytosolic proteins of L929 cells were carefully extracted with lysis 
buffer containing a low dose of digitonin (12.5 |ag/ 4 x 10^  cells) which only 
permeabilized the plasma membrane but not the mitochondrial membrane. The 
proteins collected in the supernatant, were then separated by SDS-PAGE. The 
presence of cytochrome c was detected by using aptamer cy-3 and anti-cytochrome c 
antibody (Fig. 3.36). 
From the result in Fig. 3.36, it was found that both the aptamer and antibody 
could detect the release of cytochrome c from mitochondria in the TNF-a treated 
* 
cells when compared with the control. In the untreated control, no and only a small 
amount of cytochrome c were observed when probed with antibody or aptamer 
respectively suggesting that both agents are specific for cytochrome c. Unfortunately, 
both of them showed non-specific binding to the cytosolic proteins other than 
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cytochrome c. However, both the aptamer and antibody produced a time-dependent 
signals in the cells treated with TNF-a for various time intervals. The longer the 
treatment with TNF-a, the more the cytochrome c was released into the cytosol 
which appeared in the supernatant after the treatment with a low dose of digitonin. 
> 
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Fig. 3.36. Cytochrome c released in TNF-a treated L929 cells probed with 
cy-3 and anti-cytochrome c antibody. 
L929 were seeded in a 6 wells plate (1 x 10^ cells per well) overnight. The 
cells were then incubated with medium alone (control) or TNF-a (50 
ng/ml) for 3, 6 or 9 hours at 37。C, 5 % CO2. After treatment, the cells were 
washed with PBS and cytosolic cell lysate was extracted with lysis buffer 
containing a low dose of digitonin (12.5 i^g/ 4 x 10^ cells). Cellular 
proteins were then separated by 15% SDS-PAGE. The separated proteins 
were then transferred to P V D F membranes. Non-specific binding was 
blocked by 1% (w/v) BSA. The membranes were then labeled with (a) 
cy-3 in 1% (w/v) B S A binding buffer (1:400) or (b) anti-cytochrome c in 
10/0 (w/v) B S A TBS-T (1:1000) for 1 hour and then labeled with 
streptavidin H R P (1:10000) or anti-mouse H R P conjugated antibody 
(1:1000) respectively for another hour. ECL assay was done and signal was 
exposed on X-ray films. 
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3.6.2 Detection of the cytochrome c in total cell lysate after treatment of TNF-a 
From the results above, the release of cytochrome c from mitochondria could be ‘ 
detected by the anti-cytochrome c antibody or aptamer from the cytosolic proteins 
without the permeabilization of mitochondria. In this part, total cell lysate were 
extracted from L929 cells after treatment of TNF-a by lysis buffer with a high dose 
of digitonin (400 \x.%l 4 x 10^ cells) which permeabilized the whole cell including the 
mitochondrial membrane. All the cytochrome c in the cells before or after released 
from the mitochondria would be collected. The proteins collected were then 
separated by SDS-PAGE. And the presence of cytochrome c was detected by using 
aptamer cy-3 and anti-cytochrome c antibody (Fig. 3.37). 
In the total cell lysate, it should contain all the cytochrome c in the cells no 
matter they are present in the mitochondria or cytosol. The amount of the 
cytochrome c in the same number of cells should be the same. From the results 
probed with antibody (Fig. 3.37 b), it can be seen that the levels of cytochrome c in 
total cell lysate before and after treatment of TNF-a for 3, 6, and 9 hours were more 
or less the same. However, from the results probed with cy-3, it was found that the 
levels of cytochrome c in the total cell lysate of the TNF-ot treated group was not the 
same as that of the untreated group (Fig. 3.37 a). The level and pattern of 
cytochrome c in Fig. 3.37a were in a similar pattern as the one observed in Fig. 3.36. 
This suggests that aptamer cy-3 could recognize the cytochrome c released from 
mitochondria with a high affinity than the one in the mitochondria. This discrepancy 
may be due to the fact that cytochrome c released from mitochondria has 
conformational change after the induction of apoptosis (Jemmerson et al, 1999). 
Therefore, it is possible that cy-3 may have a selective binding ability to the form of 
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cytochrome c that is released from the mitochondria of apoptotic cells. 
(b) Probed by 
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Fig. 3.37. Cytochrome c in total lysate of L929 cells with or without 
treatment of TNF-a probed with cy-3 and anti-cytochrome c 
antibody. 
L929 were seeded in a 6 wells plate (1 x 10^ cells per well) overnight. The 
cells were then incubated with m e d m m alone (control) or TNF-a (50 
ng/ml) for 3, 6 or 9 hours at 37 °C, 5 % CO2. After treatment, the cells were 
washed with PBS and total cell lysate were extracted with lysis buffer 
containing a high dose of digitonin (400 |ig/ 4 x 10^ cells). Cellular 
proteins were then separated by 15% SDS-PAGE. The separated proteins 
were then transferred to P V D F membranes. Non-specific binding was 
blocked by 1% (w/v) BSA. The membranes were then labeled with (a) 
‘ cy-3 in 1% (w/v) B S A binding buffer (1:400) or (b) anti-cytochrome c 
antibody in 1% (w/v) B S A TBS-T (1:1000) for 1 hour and then labeled 
with streptavidin H R P (1:10000) or anti-mouse H R P conjugated antibody 
(1:1000) respectively for another hour. E C L assay was done and signal was 
exposed on X-ray films. 
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3.6.3 Detection of cytochrome c in different cellular compartments after 
treatment of TNF-a 
To confirm these interesting results, we tried to lyse cells with different dosages 
of digitonin. Under this experimental condition, the degrees of permeabilization of 
cell membranes are different. With lysis buffer with a low dose of digitonin, only 
cytosolic proteins can be obtained; while that with a high dose of digitonin, the 
proteins in the mitochondria can also be extracted. 
After treatment of L929 cells with TNF-a or medium alone for 9 hours, 
proteins were extracted from the same group of cells by lysis buffer stepwisely with 
increasing dosages of digitonin starting from 12.5 |ig of digitonin. In this preparation, 
an increasing amount of cytochrome c should be obtained in the TNF-a untreated 
cells with an increasing dose of digitonin. The proteins were then separated by 
SDS-PAGE and labeled with anti-cytochrome c antibody or monoclonal aptamer 
cy-3. 
From the results labeled with anti-cytochrome c antibody (Fig. 3.38), it can be 
seen that cytochrome c mainly localized in the mitochondria (with the highest dose 
of digitonin used) of the cells without TNF-a treatment but located in the cytosol 
(extracted with the lowest dose of digitonin) after the treatment of TNF-a. In 
particular, a cytochrome c band with the highest intensity was observed in lane D，of 
Fig. 3.38b suggested that TNF-a had released cytochrome c from the mitochondria 
to the cytosol, with a higher concentration of digitonin, not too many cytochrome c 
could further be extracted (Fig. 3.38b C, to A，). In the control group, most of the 
cytochrome c was found in lane A with the highest digitonin concentration indicating 
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that the concentration of digitonin less than 87.5 |ig/ 4 x 10^ cells could not 
permeabilize the mitochondrial membrane (Fig. 3.38b, D to A). However, for the one 
labeled with monoclonal aptamer cy-3, only the cytochrome c located in the cytosol 
which is released from the mitochondria after treatment of TNF-a could be labeled. 
Cytochrome c released by the highest digitonin concentration (187.5 ^ ig) could not 
be recognized by cy-3 (Fig. 3.38a, lane A，） 
However, from the results of Western blotting labeled with cy-3 in the previous 
chapters, the cytochrome c in lysate extracted with a high dose of digitonin (400 ^ig/ 
4X10^ cells) from untreated cell could also be labeled. This may due to the fact that 
some of the cytochrome c was also released from mitochondria and present in 
cytosol in untreated cells (Fig. 36b). Also, cy-3 may labeled both release and 
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Fig. 3.38. Cytochrome c in cell lysate of L929 cells with or without 
treatment of TNF-a extracted with increasing dosage of 
digitonin probed with cy-3 and anti-cytochrome c antibody. 
L929 were seeded in a 6 wells plate (1 x 10^ cells per well) overnight. The 
cells were then incubated with medium alone (control) or TNF-a (50 
ng/ml) for 9 hours at 37 5 % CO2. After treatment, the cells were 
washed with PBS and cell lysate were extracted with lysis buffer 
containing various amounts of digitonin starting from 12.5 |ig digitonin 
and then stepwisely up to 187|ig (A, A，： 187.5，B，B,:87.5, C，C，： 37.5, 
D,D，：12.5 |ig digitonin/ 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE. The separated proteins were then 
transferred to P V D F membranes. Non-specific binding was blocked by 
P/o (w/v) BSA. The membranes were then labeled with (a) cy-3 in 1 % 
(w/v) B S A binding buffer (1:400) or (b) anti-cytochrome c in 1% (w/v) 
‘ B S A TBS-T (1:1000) for 1 hour and then labeled with streptavidin H R P 
(1:10000) or anti-mouse H R P conjugated antibody (1:1000) respectively 
for another hour. E C L assay was done and signal was exposed on X-ray 
films. 
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To find out if monoclonal aptamer cy-3 labeled the same protein as the 
anti-cytochrome c antibody, the same membrane was incubated with 
anti-cytochrome c antibody and its secondary antibody with HRP. From the ECL 
results, it was found that at the size of 15kDa, only one band was observed 
suggesting the protein band that labeled with cy-3 or antibody was the same (Fig. 
3.39a). 
Next, we wanted to test if cy-3 could block the binding of anti-cytochrome c 
antibody to cytochrome c. This was done by pre-blocked the cytochrome c by cy-3 
before labeling the protein with the anti-cytochrome c antibody and its secondary 
antibody. In the absence of streptavidin HRP, the signal produced caused only by the 
antibody. From the results, it was found that not too many bands other than 
cytochrome c were obtained (Fig. 3.39a). Moreover, the cytochrome c band 
intensities (Fig. 3.39b) were more or less the same as the one labeled with antibody 
alone (without cy-3 pre-blocked (Fig. 3.38b)). Also, in the P V D F membrane with 
cy-3 and in the presence of streptavidin H ^ , the Western blot was similar to Fig. 
3.38a. This suggests that cy-3 could not block the binding of anti-cytochrome c 
antibody to its ligand. Taken together, our results suggest that cy-3 could 
differentiate the cytochrome c released from the mitochondria of apoptotic cells and 
those remained in the mitochondria as well as the apo-cytochrome c in the cytosol. 
> 
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(a) Pre labeled by cy-3 (b) Pre blocked by cy-3 
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Fig. 3.39. Cytochrome c in cell lysate of L929 cells with or without 
treatment of TNF-a extracted with increasing dosage of 
digitonin. 
L929 were seeded in a 6 wells plate (1 x 10^ cells per well) overnight. The 
cells were then incubated with medium alone (control) or TNF-a (50 
ng/ml) for 9 hours at 37 °C, 5 % CO2. After treatment, the cells were 
washed with PBS and cell lysate«were extracted with lysis buffer 
containing various amounts of digitonin starting from 12.5 |ig digitonin 
and then stepwisely up to 187|ig (A, A，： 187.5, B,B':87.5, C，C,: 37.5， 
D,D':12.5 \ig digitonin/ 4 x 10^ cells). Cellular proteins were then 
separated by 15% SDS-PAGE. The separated proteins were then 
transferred to P V D F membranes. Non-specific binding was blocked by 1% 
(w/v) BSA. The membranes were then labeled with cy-3 in 1% (w/v) B S A 
, binding buffer and then (a) with (pre-labeled) or (b) without (pre-blocked) 
streptavidin H R P (1:10000) for 1 hour. The two membranes were then 
labeled with anti-cytochrome c in 1% (w/v) B S A TBS-T (1:1000) for 1 
hour and anti-mouse H R P conjugated antibody (1:1000) for another hour. 
ECL assay was done and signal was exposed on X-ray films. 
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4.1. General information 
For more than one decade, aptamer technology has been developed and many 
different oligonucleotides have been selected to recognize different types of targets. 
These targets include drugs (Jenison R D et al” 1994), amino acids (Mannironi et al., 
2000), proteins (Tuerk et al” 1992), organic dyes, co-factors, peptides, metal ions, 
nucleotide base analogs and virus (Pan et al” 1995) (Table 1.1). Although aptamers 
were selected to recognize different proteins, their specificity was not verified and 
they were seldom proved to bind to their target specifically from a mixture of 
different proteins (Radrizzani et al, 1999). In m y project, aptamers against 
cytochrome c were selected from a pool of oligonucleotides and they were tested to 
label cytochrome c from a mixture of proteins in a cell lysate by using Western blot 
analysis. 
4.1.1 The pool of oligonucleotides 
Starting from a D N A pool with 76 nucleotides oligonucleotides which consists 
of 40 random nucleotides in the central region and 18 nucleotides each at the 5' and 
3’ flanked ends, aptamers were selected against cytochrome c. 
‘4.1.2 Design of oligonucleotides 
Until now, it is still not entirely clear to know what the optimal number of 
nucleotides should be in the D N A library. Oligonucleotides used for the selection of 
aptamers usually contain 30 to 60 randomized nucleotides (Gold et al., 1995). 
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Longer molecules seems more attractive that they provide a linear increase in the 
probability of finding a defined sequence and a combinatorial increase in the 
probability of finding two or more interacting sequences. Moreover, they will fold 
into more complex and stable structures than shorter ones. However, irrespective of 
whether shorter or longer random sequence libraries are used, the overall complexity 
of the population is limited by D N A synthesis chemistry to a total of 
different sequences. With this constrain, randomized libraries usually contain all 
possible sequences from 22 to 27 residues in length ~ l O i�，- lO’. 
Under this limitation, a frequent misconception is that a longer pool will be less 
representative than shorter one in terms of the completeness of randomized 
sequences. For example, the number of possible 40-mers is == and thus a 
library of different molecules samples only 10"^  of 40-mer space. From this 
calculation, the chance of the loss of the sequences in a pool increases with the 
length of the sequences used. However, longer pools will subsume the shorter pools 
(longer pool contains all possibility of shorter pool) and in addition, they will contain 
a diverse and perhaps critical representation of longer sequence motifs. 
‘ In addition, in most oligonucleotide synthesis, the yield and quality of the 
product decrease dramatically when the total length exceeds 100 nucleotides (Shi et 
al., 1997). After balancing the complexity and the loss of the sequence in the pool, 
oligonucleotides with 40 random nucleotides in between two flanked ends which 
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used for amplification were used in our project. 
4.1.3 SELEX 
SELEX composes of in vitro selection and amplification. In vitro selection has 
proven to be an extremely useful technique for defining protein-binding sites and for 
deriving novel binding species (aptamers) from random sequence populations 
(Famulok et al., 1998, Eaton et al., 1997). In our selection, the first round of 
selection started with 100 pmol of the pool of oligonucleotides, which contains about 
6 X 10i3 different sequences. Although, it could not cover all the possibility made by 
40 random nucleotides, it reached the limitation of the D N A synthesis chemistry, 
thus, the loss of the possible sequences was reduced to minimum. 
4.1.3.1 Buffer condition of selection 
Buffer conditions are important to stabilize the active conformation of a target 
molecule. In our selection, the binding buffer we used was composed of 10 m M 
HEPES, 75 m M NaCl, 5 m M M g C b and I m M CaCb. High concentrations of 
monovalent cations (50 to 1000 m M are typically used) tend to quell nonspecific 
binding of species to targets (Binkley et al” 1995). In contrary, divalent cations such 
‘as Mg2+ and Ca^^ can promote non-specific binding. However, they are important for 
I 
the formation of nucleic acid secondary and tertiary structures. Thus, low 
concentrations of divalent ions (1 to 10 m M ) are used in our project (Marshall et al., 
2000). 
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4.1.3.2 Binding equilibrium 
During the selection, the binding reaction should be allowed to reach 
equilibrium. For almost all aptamers, this requires more seconds. However, because 
the association between aptamers and their targets may involve an induced fit 
mechanism (Westhof et aL, 1997), it is wise to allow the binding reaction to 
equilibrate from 5 to 60 minutes. 
4.1.3.3 Prevalence of matrix-binding species 
In our selection, aptamers were selected against cytochrome c coated on P V D F 
membrane. Some nucleic acids were found to bind to modified cellulose filters in a 
target-independent manner (Tuerk et ai., 1992). Also, if the stringency of the 
selection employing filter binding as a separation technique is too high at the 
beginning or the stringency is increased too quickly in subsequent rounds, 
filter-binding species always stands out. To avoid this problem, a negative, selection 
step (counter selection) is frequently employed. 
i 
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4.2. Selection 
In our selection, the non-specific site on PVDF membrane was blocked by 1% 
(w/v) BSA. And the oligonucleotides were first counter-selected against a B S A 
blocked P V D F membrane. That is, those sequences that bound to B S A or PVDF 
membrane were discarded. Only the oligonucleotides remained were used to be 
selected against the target. With counter selection, we could make sure that only 
sequences bound to cytochrome c but not B S A or PVDF membrane were chosen. 
After binding, the membrane was washed with binding buffer. This could 
remove those unbound or loosely bound sequences. The bound oligonucleotides 
were then eluted by elution buffer under heat. The oligonucleotides collected were 
then amplified by PCR. 
4.2.1 Cycle numbers of PCR _ 
Throughout the amplification of PCR, the aptamers were amplified with the 
primers which were complementary to the 5, and 3, flanked ends of the 
oligonucleotides. To amplify the single-stranded sense oligonucleotides, excess 5' 
forward primer (30 times more than 3，reverse primer) was added to the PCR 
‘reaction. Theoretically, only those oligonucleotides with the same size with the 
aptamers could be produced. However, from the gel photo (Fig. 3.1) of P C R 
products produced by different P C R cycles, there were some high molecular weight 
products produced in the later rounds of PCR. However, the reason of the production 
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of these high molecular weight products is still unknown but these products did not 
interfere with the eventual isolation of high affinity aptamers (Cox et al” 2000). To 
prevent these unwanted products, the P C R cycle number was optimized and our 
results indicated that 15 cycles was the optimal number (Fig. 3.1). 
I 
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4.3. Assay of aptamers selected 
4.3.1 The use of biotin-streptavidin for recognition 
After seven rounds of selection, aptamers selected were amplified and 
biotinylated by P C R with the use of excess biotinylated 5' forward primer. By this 
arrangement, single-stranded sense oligonucleotides were amplified and conjugated 
with biotin at 5' end. The biotin could be recognized by streptavidin with high 
affinity (Gretch et al” 1987). With suitable substrate, colour product or 
chemiluminescence can be produced by the H R P conjugated on the streptavidin. 
These signals could then be detected by plate reader, x-ray film or fluorescence plate 
reader. -
4.3.2 Polyclonal aptamers 
Using dot blot assay, cytochrome c dotted on the P V D F membrane was labeled 
with the aptamers. Our results show that the aptamers selected could label 
cytochrome c in a dose-dependent manner, and they did not bound B S A which acted 
as a blocking agent on the P V D F membrane (Fig. 3.2). 
4.3.3 Monoclonal aptamer 
After SELEX, the aptamers obtained were polyclonal. They consisted of many 
oligonucleotides with different sequences in the core region. In the polyclonal 
aptamers, it might contain some sequences that had lower affinity to the target or that 
could bind to the matrix. Thus, monoclonal aptamers were obtained by cloning 
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technique. 
4.3.4 Cy-3 shows the highest affinity to cytochrome c 
From the polyclonal aptamers, 9 monoclonal aptamers were obtained 
successfully (Fig. 3.3). By the binding test of cy-1 to cy-4, cy3 was found to have the 
highest affinity to cytochrome c among the four (Fig. 3.4). Cy-3 was then used for 
further tests. By dot blot analysis and Western blot of pure cytochrome c, the 
detection limitation of cy-3 in our experimental conditions was found to be 0.25 and 
0.5 |ig (Fig. 3.5 and Fig. 3.8) respectively. By the test of ELISA, cy-3 showed a 
linear relationship with the amount of cytochrome c in the range of 0-4 \igl 100 [i\ 
per well and became level off when the amount of cytochrome c was greater than 4 
|ig (Fig. 3.6). Cy-3 was also found to bind cytochrome c from different species such 
as horse, rat, tuna, yeast and chicken (Fig. 3.9). However, cy-3 could not block the 
binding between cytochrome c and anti-cytochrome c antibody (Fig. 3.7). This 
suggests that the cy-3 and antibody have different recognition sites on the 
cytochrome c molecule. 
4.3.5 The presence of non-specific binding 
‘ Next, we tested whether cy-3 was able to bind cytochrome c from a mixture of 
proteins. Using lysis buffer with a high dose of digitonin (400 |ig/4 x 10^ cells), all 
the proteins in the cells including cytochrome c in the mitochondria could be 
extracted. From our results, it was found that cy-3 could bind to cytochrome c and 
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cytosolic proteins from a mixture of proteins (Fig. 3.10). This may be due to the fact 
that cy-3 could bind to some of the cytosolic proteins non-specifically. However, 
after testing the other 8 monoclonal aptamers, the results showed that all of them 
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4.4. Counter selection against cell lysate 
In the antibody production, all the B clones are screened before maturation and 
the B clones and their antibodies that recognize self proteins are deleted from our 
immune system. This clonal deletion can prevent auto-immunity in our body. 
However, oligonucleotides used for selection contained all the random sequences 
which might contain some aptamers that could recognize the cellular proteins that 
are not immunogenic. 
To overcome this problem, oligonucleotides were counter selected against cell 
lysate to exclude those oligonucleotides which could recognize cellular proteins from 
the pool. Proteins for counter selection were extracted from cells with a low dose of 
digitonin (12.5 jig /4 x 10^ cells). Using this low dose of digitonin, only the proteins 
in the cytosol but not organelles (such as cytochrome c in mitochondria) were 
extracted. Therefore, oligonucleotides -bound to cytosolic proteins but not 
cytochrome c were removed by the counter selection. 
In m y project, three different methods were examined to remove those 
oligonucleotides that could bind cytosolic proteins. The first one is the counter 
‘selection against cytosolic proteins as mentioned before. Before the selection, 
oligonucleotides were first incubated with a membrane coated with cytosolic 
proteins (extracted with a low dose of digitonin) followed by a second selection 
against cytochrome c. 
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The second one is by the use of fixed cells. After cells were fixed by 0.3% 
glutaraldehyde in PBS, the membranes were permeabilized and oligonucleotides 
could freely enter the cells. After incubation, some of the oligonucleotides would 
bind to their specific targets including cytochrome c in the cells. After washing away 
those unbound oligonucleotides, cytochrome c was added to elute the aptamers that 
bound to cytochrome c specifically. During the elution, cytochrome c was added and 
incubated with the fixed cells with decreasing time intervals to increase the 
stringency of selection. 
The stringency of selection was affected by numerous variables. Shortening the 
incubation time interval is one of the methods. In the early round of selection, less 
stringent conditions and longer incubation periods were used to maximize the 
recovery of the relatively few functional molecules present in the initial pool. 
Stringency was then increased in the later rounds as the population winnowed to 
predominantly functional molecules. 
From our results, both the aptamers selected with counter selection against 
cytosolic proteins and selected by fixed cells were found to bind to cytosolic proteins 
‘and cytochrome c (Fig. 3.12 and Fig. 3.13). This suggests that counter selection was 
not clean enough. Thus, we tried the third method. Theoretically, those aptamers 
bind to the cytochrome c on the P V D F membrane after P A G E should be the 
oligonucleotides that bound to cytochrome c specifically. Thus, the aptamers were 
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eluted from the band of cytochrome c after the Western blot analysis. The aptamers 
eluted were then reamplified and tested for the binding with the cell lysate again. 
Unfortunately, the aptamers eluted from the bands of cytochrome c still showed 
non-specific binding to cytosolic proteins (Fig. 3.14). 
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4.5. Primer testing 
From the results in Figs. 3.10 - 3.14, they all showed non-specific binding with 
a similar pattern. This may be due to the fact that there might be a common item 
present in the labeling solution that could bind cytosolic proteins. In all the P C R 
reactions, biotinylated 5' forward primer was in excess and they contained the site 
that could be recognized by streptavidin H R P for signal generation. Thus, we next 
tested whether the 5' forward primer interacted with the proteins in the cell lysate. 
It is clear from our result that the primer could bind to cytosolic proteins but not 
cytochrome c (Fig. 3.15). However, after we eliminated the excess primers from the 
P C R product before labeling, cy-3 still showed the non-specific binding to cytosolic 
proteins (Fig. 3.16). 
To eliminate the primer sequence atJhe ends of aptamers, aptamers with core 
sequence were prepared by D N A synthesis chemistry as the aptamers could no 
longer be amplified from plasmids without the flanked primer ends through PCR. 
After sequencing, the sequences of cy-1 to cy-3 were obtained. 
‘ With the information from sequencing, the core sequence of cy-3 without 
flanked primer ends was synthesized with a biotin conjugated at the 5' end. After 
testing its binding to cell lysate, it was found that the core sequence also bound 
cytochrome c and cytosolic proteins (Fig. 3.17). 
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In the literature, Bianchini's group (2001) was the only group that reported the 
development of monoclonal aptamers against cellular proteins and showed single 
band in Western blot analysis (Bianchini et aL, 2001; Radrizzani et a!., 1999). This 
suggests that their primer set might be a good starting material for aptamer 
development. With this thought in our mind, same primers with biotin conjugated 
were synthesized and their binding to cell lysate was examined. 
After testing the binding of the primers of ERK2-F0R and ERK2-REV to cell 
lysate in the conditions we used, our results (Fig. 3.22) showed that the primers from 
Bianchini group also bound cytosolic proteins with the same binding pattern as we 
saw before. However, with the labeling conditions used by Bianchini et aL, (2001) 
(blocked the P V D F membrane with 5 % (w/v) milk), his primer pair did not show 
any non-specific binding to the cytosolic proteins. These results suggested that the 
problem of the non-specific binding may be due to the inefficiency of blocking when 
1% B S A (w/v) was used as blocking agent. 
» 
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4.6. Sequences and secondary structures of monoclonal 
aptamer 
According to the sequencing results, all three aptamers cy-1 to cy-3 were found 
to be C G rich sequences in the middle core. 
The binding of aptamer to its target was known to be achieved by its three 
dimensional structures. However, little is known about the tertiary structures of the 
aptamers. As for the secondary structures, a wide variety of secondary structures 
were shown to be used by aptamers, for examples, stem-loops, stem-bulge-stems, 
pseudoknots, and G-quartets (Lorsch et al” 1996). 
The secondary structures of cy-1 to cy-3 with or without the flanked primer 
sequences were predicted by using Vienna R N A Secondary Structure Prediction and 
Comparison Programme (Fig. 3.18). Our-results showed that the structures of the 
three aptamers were different but cy-2 and cy-3 were quite similar. Moreover, the 
secondary structures of the core sequence of cy-1 to cy-3 were quite similar 
corresponding to that of their whole sequences. At the moment, we do not know why 
these aptamers, though with different nucleotide sequence, bound cytosolic protein 
‘in a similar pattern. 
From the sequencing information, we tried to introduce mutation to the aptamer 
cy-3. With mutation, the predicated secondary structures were found to be different 
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from that of cy-3 (Fig. 3.20). Theoretically, the change of the primary sequence of 
aptamer could affect the binding affinity of the structures. From our results (Fig. 
3.21), it was found that the affinity of one of the mutants (cy-3-2) became lowered 
after mutation, while the other one increased (in terms of intensity). However, the 
binding of the aptamer to its target is mediated by the tertiary structure, the 
secondary structure might not show the real picture. 
Most aptamers were found to have conformational change upon ligand binding. 
For the ATP aptamer, the cyanocobalamin aptamer (Wilson et al., 1995) and the 
guanosine/arginine joint aptamer (Connell et al” 1993), their bases become 
hypersensitive to chemical modification in the presence of ligand. These suggest that 
the aptamers undergo structural changes when they bind to their ligands. Moreover, 
aptamers against theophylline show major changes by N M R spectra when 
theophylline is present. This observation Jed Jenison et al., (1994) to conclude that 
aptamer changes their structure upon ligand binding (Davies et al” 1993). It was 
suggested that these sorts of structural changes were a common feature in R N A 
recognition (Lorsch et al., 1996). In this connection, we do not know whether our 
aptamers showed similar property. 
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4.7. Elimination of non-specific binding 
4.7.1 Non-specific binding may be mediated by sequence-independent 
recognition 
The folding of oligonucleotide can be destroyed by heat at 95 °C, and it will 
become linear in structure. From the results of heat dissociation, the non-specific 
binding could not be removed by heating at 95 °C (Fig. 3.24). This indicated that the 
non-specific binding might not be mediated by the sequence-dependent recognition 
of the oligonucleotides. It may be a result of charge-charge interactions between the 
D N A and proteins or due to the presence of proteins which could bind D N A 
molecules on the P V D F membrane. 
4.7.2 Elimination of non-specific binding by milk 
Next, we tested the use of 1% milk and 5 % milk as blocking agents. From our 
results, 5 % milk could block the non-specific binding of the 5' forward primers 
effectively (Fig. 3.25). However, 5 % milk could also block the binding of cy-3 to 
cytochrome c (Fig. 3.27). 
The folding of oligonucleotide depends on the condition of buffer such as pH 
‘and salt concentration. Lorsch et aL, (1994) showed that the aptamers against 
cyanocobalamin could only form complexes in the buffer conditions in which they 
were originally selected; alteration in the buffer conditions for selection led to an 
alteration of aptamer sequences. This means that the conditions under which the 
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selection is carried out will largely determine what binding species are isolated. 
When non-fat milk was used as blocking agents, the composition of the binding 
buffer such as calcium, magnesium, zinc and phosphorous was changed which 
affects the conformations of oligonucleotides. 
From our results, it was found that milk could not dissociate the non-specific 
binding of the primers to the cytosolic proteins but it prevented the binding between 
them (Fig. 3.26). After the salt concentration of binding buffer had been changed, the 
conformations of the oligonucleotides should be altered. As our results showed that 
milk could not dissociate the non-specific binding, this further suggested that the 
non-specific binding was not mediated by the sequence-specific recognition. 
As mentioned before, the condition of binding buffer may alter the 
conformation of the oligonucleotides and different oligonucleotides may be selected 
to the same target in different buffer conditions. Thus, the monoclonal aptamer 
selected with B S A might not be suitable for the use in the presence of milk. 
Therefore, we started another set of selection with the same condition of labeling in 
‘the presence of milk. In this set of selection, oligonucleotides after counter selection 
against milk were allowed to bind to the denatured cytochrome c which was in the 
same form as in Western blotting (e.g. with SDS after boiling). Subsequently, the 
bound oligonucleotides were eluted with the use of native cytochrome c. With this 
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Strategy, the aptamers selected were supposed to bind to both the native and 
denatured cytochrome c. However, from the results of Western blotting, nothing 
could be labeled with the aptamers selected (Fig. 3.28). 
4.7.3 Eliminate the non-specific binding by using DNA 
As indicated by the results of dissociation of non-specific binding by milk and 
heating, the binding between proteins and oligonucleotides may be mediated by the 
sequence-independent binding. In this part, D N A was used as blocking agent to 
reduce the binding of oligonucleotides to DNA-binding proteins in the cell lysate. 
From our results, it was found that 150 |ig D N A could block the non-specific binding 
effectively (Fig. 3.29). However, similar to the results with milk, D N A could block 
the binding of cy-1 to cy-4 to cytochrome c (Fig. 3.30). 
The presence of D N A used as blocking agent might interfere the recognition 
site of aptamers cy-1 to cy-4 to the cytochrome c. In the new set of selection, the 
target was blocked with 1 % B S A and then with D N A before selection. From our 
results, it was found that nothing could be labeled with the aptamers again (Fig. 
3.31). 
* 
There was one possibility that nucleic acid might be present in the cell lysate 
during protein extraction that interacts with our aptamers. To remove the nucleic acid 
in the cell lysate, DNase, RNase or both were used to treat the lysate before testing 
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for the non-specific binding. From our results, it was found that the nucleic acid in 
the cell lysate did not play an important role in the non-specific binding (Fig. 3.32). 
» 
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4.8. Photo-aptamer 
Photo-aptamers were shown to have high selectivity and specificity. By 
replacing thymidine with 5‘-bromo-2‘-deoxyuridine (Meisenheimer et al., 1997), 
photo-aptamer can form photo-cross linking with the aromatic and sulfur-bearing 
amino acid residues of the protein targets which are in suitable proximity (Ito et al., 
1980; Swanson et a/” 1981; Dietz et al., 1987). The photo-aptamers against 
recombinant human basic fibroblast growth factoriss (bFGFiss) have been 
successfully selected (Golden et al., 1999). The bFGFiss specific photo-aptamers 
have a high sensitivity for bFGFiss when compared with the commercially available 
monoclonal antibodies (Golden et al., 2000). 
In this set of selection, a fixed ratio of oligonucleotides to proteins was allowed 
to react. If a large amount of target is available for binding, then more aptamers with 
lower association constants will be retained. Thus, the amount of oligonucleotides 
should be in excess when compared to that of the targets. In our experiment, 40 pmol 
oligonucleotides were incubated with 1.2 pmol cytochrome c in each round of 
selection, and their ratio was about 33:1. 
‘ After five rounds of selection, photo-aptamers were selected against 
cytochrome c. From the results, it was found that the photo-aptamers could bind to 
cytochrome c with 1% B S A (w/v) with or without U V irradiation. However, for the 
one labeled in the presence of 5 % milk, the non-specific binding was blocked and 
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photo-aptamers could not label the cytochrome c in the presence or absence of U V 
irradiation (Fig. 3.34). It seems likely that photo-aptamer could not be used to solve 
the problem of non-specific binding. After adding the photo-aptamers, 
oligonucleotides that loosely bound on the P V D F membrane were not washed away 
and formed cross linking with the protein under U V irradiation (Fig. 3.34). 
Another test was employed to test the photo-aptamers. From the results of 
immuno-precipitation, it showed that photo-aptamer could pick up cytochrome c 
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4.9. Application of the monoclonal aptamer cy-3 
After all these methods, we still could not eliminate the non-specific binding 
between the monoclonal aptamer with cellular proteins. Next, we tried to concentrate 
ourselves on the cytochrome c band for the semi-quantification of cytochrome c with 
SDS-PAGE. To investigate this, we tried to use aptamer cy-3 again to probe the 
cytochrome c released from TNF-a treated L929 cells. 
Cytochrome c is a water soluble protein locates in the space between the inner 
and outer mitochondrial membrane. The precursor of cytochrome c, apocytochrome 
c，is synthesized in ..the cytoplasm. Upon translocation into the mitochondria, 
cytochrome c refolds and acquires a heme moiety required for functionality in the 
mitochondrial respiration chain. The heme-bound form of cytochrome c is called 
holocytochrome c. Cytochrome c is an essential component of the mitochondrial 
respiratory chain (Liu et al., 1996) and it also plays an important role in apoptosis. 
Apoptotic stimulus triggers the release of cytochrome c from the mitochondria into 
cytosol where it binds to Apaf-1. The cytochrome c/Apaf-1 complex activates 
caspase-9, which then activates caspase-3 and other downstream caspases. 
4.9.1 Aptamer can label cytochrome c as antibody does 
TNF-a was found to induce the release of cytochrome c from the mitochondria 
by using anti-cytochrome c antibody (Yuen et al, 2000). From our results, it was 
found that although the monoclonal aptamer cy-3 had non-specific binding to other 
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cytosolic proteins, it could label cytochrome c as antibody did. 
To further confirm the target of cy-3 is cytochrome c, the cy-3 labeled protein 
band was cut out. W e tried to sequence the N-terminus of the polypeptide chain in 
the 15 kDa band by Edman reaction. In Edman reaction, the polypeptide chain reacts 
with phenylisothiocyanate to form a covalent bond to the NH2-terminal amino acid. 
Under acidic condition, this derivative catalyzes an intramolecular cyclization that 
results in a cleavage of the NH2-temiinal amino acid from the polypeptide chain as a 
phenylthiophydantoin derivative. This NH2-tenninal amino acid derivative can be 
separated chromatographically and identified against standards. The polypeptide 
chain minus the NH2-tenninal amino acid is then isolated, and the Edman reaction is 
repeated to identify the next NH2-terminal amino acid. Unfortunately, our 
sequencing failed to produce any signal. It is well received that if a polypeptide 
chain was modified such as the addition of saccharide, the presence of the saccharide 
may block the reaction with phenylisothiocyanate and disrupt the sequencing of the 
protein. In fact, cytochrome c was found to have an acetylation at its N-terminus that 
affected the peptide sequencing failed (Margoliash E et al., 1961). 
‘ To show the release of cytochrome c from mitochondria to the cytosol, the 
plasma membrane was carefully permeabilized by a low dose of digitonin (12.5 |ig/ 
4 X 106 cells). Cy-3 was able to demonstrate the release of cytochrome c from the 
mitochondria of cells treated with TNF-a in a time-dependent manner (Fig. 3.34). 
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In mitochondria, cytochrome c was believed to have interaction with the 
phospholipid-rich inner mitochondrial membrane (Salamon et al, 1996). When 
cytochrome c associates with synthetic anionic phospholipids vesicles, it shows 
conformational change. This involves an opening of the heme crevice resulting from 
the loss of both the iron-methionine 80 ligation (Spooner et aL, 1992) and H-bonds 
between amino acid side chains and one of the heme propionates (Soussi et aL, 
1990)，as well as the destabilization of the tertiary structure of the polypeptide 
detected by the accessibility of the backbone amides to hydrogen-deuterium 
exchange (Muga et aL, 1991). By a monoclonal antibody 1D3 which recognizes the 
omega loop region around residue 44 located to the right and below the exposed 
heme crevice, a conformational change in cytochrome c was observed in apoptotic or 
necrotic cells but not in healthy cells (Jemmerson et al., 1999). This 
conformationally altered cytochrome c appears to be important in the apoptotic cell 
death. 
When we tried to use the monoclonal aptamer cy-3 to label the total lysate of 
cells treated with TNF-a, to our surprise, the results showed that cy-3 could label the 
cytochrome c in the total cell lysate (Fig. 3.37a) in a pattern similar to the one found 
‘in the cytosolic proteins (Fig. 3.36a). In contrast, anti-cytochrome c antibody showed 
a constant intensity in the cytochrome c bands from the cells with different 
treatments (Fig. 3.37b). This suggests that cy-3 could differentiate the cytochrome c 
released from mitochondria with those remained in the organelles. Mechanistically, 
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aptamer cy-3 might have a higher affinity to the cytochrome c with the 
conformational change after the induction of apoptosis (Fig. 3.37). 
Suen et al., (2000) had showed that lysis buffer with different dosages of 
digitonin could isolate the cellular proteins in different compartments of cells. The 
higher the dosage of digitonin, the higher the degree of permeabilization of the cell 
membrane and the cell proteins from the inner organelles of the cells can be 
extracted. From the results with anti-cytochrome c antibody, it was found that 
cytochrome c was mainly localized in the organelles presumably the mitochondria 
that require a high dose of digitonin to permeabilize in the cells without TNF-a 
treatment. For the cells with TNF-a treatment, cytochrome c was found in the 
cytosol and could be extracted with a lower dose of digitonin (Fig. 3.38 b). However, 
results from the monoclonal aptamer cy-3 indicated that only the cytochrome c 
located in the cytosol released from the mitochondria was labeled (Fig. 3.38 a). 
To confirm this observation, cytosolic proteins from apoptotic L929 cells 
were probed with cy-3 and subsequently with anti-cytochrome c antibody. The 
anti-cytochrome c we used is from clone 7H8.2C12, its epitope is between amino 
/ 
acids 93-104 of pigeon cytochrome c and it can recognize cytochrome c from horse, 
human, mouse, pigeon and rat. Our results showed that the cytochrome c band 
originally not be seen in the lanes of untreated group at 15 kDa appeared when 
anti-cytochrome c antibody was used (Fig. 3.39a). This suggests that cytochrome c 
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existed in the gel when probed with aptamer cy-3. Moreover, the prior binding of 
cy-3 to cytochrome c did not affect the binding of antibody (Fig. 3.39b) indicating 
that the recognition site of cytochrome c by antibody and that of aptamers were 
different. In fact, this had been shown in the competitive ELISA assay (Fig. 3.6). 
Taken together, cy-3 could differentiate the intact cytochrome c and those released 
from apoptotic cells. 
\ 
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4.10. Conclusion I 
Monoclonal aptamers were selected against cytochrome c. However, they 
showed some non-specific bindings to other cytosolic proteins possibly through a 
sequence-independent manner. Although these non-specific bindings could be 
blocked by 5 % (w/v) milk or D N A , aptamer was failed to generate signals against its 
ligand cytochrome c under these condition. 
In out study, it was found that our cy-3 bound to cytochrome c at a different site 
from that by anti-cytochrome c antibody (clone no. 7H8.2C12). By focusing on the 
band of cytochrome c, .monoclonal aptamer could still be used for semi- quantization 
by Western blot analysis. Cy-3 was found to recognize the cytochrome c after 
apoptosis induction with a high specificity. This provides a unique property to our 
cy-3 for the analysis of cytochrome c release during apoptosis. 
I 
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4.11. Conclusion II 
Started from the early 1990s, aptamer technology was developed and many 
different aptamers have been selected for a wide range of targets. Automated 
selection process was also developed in 2000 (Cox et a!.’ 2001). However, it seems 
likely that not all the molecules can be used as the target for selection. Stanlis et al., 
(2003) has reported that they failed to identify aptamer against EGFP according to 
the procedure of SELEX and even with the help of a company which specialize in 
the aptamer selection. The reason for this was unknown. 
Actually, the technology of aptamer was still at its infant stage. For example, we 
do not know the three-dimensional folding mechanism of the oligonucleotide, the 
relationship between the binding and the structure of aptamer, how the buffer 
conditions affect the folding and the binding of the aptamer etc. These questions are 
waiting to be solved. From the literatures of aptamer selection, there are many 
different ideas and conditions for the selection process and thus, the process of 
selection is still need to be optimized. 
Among the aptamers selected, some were proved to have the ability to 
,distinguish compounds with similar structures. However, they were seldom proved 
» 
to pick up their targets from a mixture of proteins (Bianchini et al, 2001). This 
observation suggests that aptamer will play a complementary role but not replace the 
existing immunodiagnostic methods at this moment (Rye et al” 2000). For this 
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young technology, more research work is needed to make it perfect. Our aptamers 
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